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SUMMARY 
Large clinical trials and meta-analytic studies revealed that most of the antiarrhythmic 
drugs are associated with proarrhythmia and do not increase long-term survival in man. Thus, 
better understanding of proarrhythmic events and better antiarrhythmic drugs are required. 
The antiarrhythmic activity of almokalant and d-sotalol (selective K + channel inhibitors, 
Class in antiarrhythmics) were tested in anesthetized rabbits subjected to coronary artery 
occlusion and reperfiision. Both drugs prevented reperfusion-induced ventricular fibrillation 
(VF). The proarrhythmic effects of continuous almokalant infusions and increasing doses of d-
sotalol, almokalant, quinidine and amiodarone were examined in at-adrenoceptor stimulated 
anesthetized rabbits. Almokalant and d-sotalol evoked not only torsade de pointes (TdP), but 
also ventricular tachycardia (different from TdP) and VF. The high proarrhythmic activity of 
these drugs compromises their antiarrhythmic efficacy and precludes their use as antifibrillatory 
agents. 
Mibefradil, a blocker of both L and T Ca 2 + channels, was compared with the (±)-
verapamil for effects on ischemia- and reperfusion-induced VF in isolated rat hearts, and the 
role of putative ischemia-selective L-channel block was also examined. Mibefradil was less 
potent than (±)-verapamil as an antiarrhythmic drug. As mibefradil is the more potent T 
channel blocker, the T channel is unlikely to represent the molecular target for the 
antiarrhythmic effects of the drug. The effects of both drugs can be explained on the basis of 
L-channel blockade within the ischemic region. Neither drug prevents VF at concentrations 
devoid of hazardous vascular and atrioventricular nodal effects. This precludes the safe use of 
mibefradil in VF suppression, and explains the lack of clinical effectiveness of (±)-verapamil. 
The antifibrillatory and proarrhythmic effects of representative Na+ channel blockers 
(Class la, lb and Ic drugs) were examined in isolated rat hearts subjected to coronary artery 
occlusion and reperfiision. The ischemia-selective VF suppression by flecaimde, and the 
ineffectiveness of clinically relevant concentrations of quinidine and lidocaine during both 
ischemia and reperfiision confirms that the spectrum of antiarrhythmic activity of Class I agents 
is narrow and weak at clinically safe 'therapeutic' concentrations. Moreover, there was a 
tendency for proarrhythmia with flecainide. These findings may explain the limited 
effectiveness of these Na+ channel inhibitors against sudden cardiac death in man. 
These results gave experimental evidence of proarrhythmic activity or limited 
effectiveness of representative agents of three major classes of antiarrhythmics and the 
methods applied provide useful experimental tool for examining both the effectiveness and the 
harmful effects of newly developed antiarrhythmic agents. 
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ACRONYMS AND ABBREVIATIONS 
AV atrioventricular 
EAD early afterdepolarization 
ECG electrocardiogram 
i.p. intraperitoneal(ly) 
i.v. intravenously) 
QTc heart rate corrected QT interval 
TdP torsade de pointes 
VF ventricular fibrillation 
VPB ventricular premature beat 
vs. versus 
VT ventricular tachycardia 
Ica-L inward L-type calcium current 
I N a inward sodium current 
IK delayed rectifier potassium current 
iKr the rapid component of the delayed rectifier potassium 
IKI inward rectifier potassium current 
I,o transient outward potassium current 
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1. INTRODUCTION 
1.1. Background of the study 
Ischemic heart disease and myocardial infarction are still the leading causes of death in 
modern societies. Thus, sudden cardiac death, which is attributable in many instances to life 
threatening arrhythmias, remains an important pharmacotherapeutic target. 
The analysis of the "Cardiac Arrhythmia Suppression Trials" (CAST-I and CAST-II) 
prompted the reconsideration of prophylactic antiarrhythmic treatment after myocardial 
infarction. The results showed that Class Ic type Na+ channel blockers increased mortality in 
survivors of myocardial infarction [1, 2]. The results of these trials and those of the 
"Electrophysiologic Study Versus Electrocardiographic Monitoring" (ESVEM) [3] and the 
"Cardiac Arrest Study in Seattle: Conventional Versus Amiodarone Drug Evaluation" 
(CASCADE) trials [4] shifted the attention to Class in antiarrhythmics. 
In the CASCADE trial amiodarone, a repolarization prolonging (Class III) 
antiarrhythmic drug with complex effects, provided better survival rate than the conventional 
antiarrhythmic drug therapy in post-myocardial infarction patients [4]. In the ESVEM trial d,l-
sotalol, another Class IU antiarrhythmic drug with antiadrenerg effects, was more effective 
than other six antiarrhythmic drugs in preventing death and recurrences of arrhythmia [3]. 
Howeyer, the "European Myocardial Infarct Amiodarone Trial" (EMIAT) and the "Canadian 
Amiodarone Myocardial Infarction Trial" (CAMIAT) demonstrated that amiodarone reduced 
arrhythmic but not overall mortality in post-myocardial infarction patients [S, 6]. Likewise, d,l-
sotalol has been shown to have neutral effects on overall mortality in post-myocardial 
infarction patients in another large clinical trial [7]. Moreover, long-term amiodarone treatment 
leads to severe side effects [8] and d,l-sotalol causes torsade de pointes arrhythmias (TdP) [9]. 
Thus, more selective Class III drugs have been developed with the expectation that the use of 
these agents will provide better efficacy and safer use. 
As a disappointment, in the "Survival With Oral d-Sotalol" (SWORD) trial d-sotalol, a 
selective Class m antiarrhythmic, was shown to increase mortality in subsets of patients with 
myocardial infarction and lowered ejection fraction [10]. On the contrary, in the "Danish 
Investigations of Arrhythmia and Mortality on Dofetilide" (DIAMOND) trial dofetilide, 
another selective Class EI antiarrhythmic, did not affect mortality in patients with severe left-
ventricular dysfunction and recent myocardial infarction [11]. However, dofetilide therapy is 
associated with an increased risk of TdP [12-14] and proarrhythmic sudden cardiac death [13]. 
In patients with coronary disease nifedipine, a dihydropyridine calcium agonist, causes 
an increase in total mortality [15]. On the contrary, data from trials of non-dihydropyridine 
calcium agonists such as diltiazem and verapamil have not demonstrated increased mortality 
rates in patients with coronary artery disease and good left ventricular function [16-19]. 
Nevertheless, convincing evidence of reduced mortality with the use of non-dihydropyridine 
Class IV antiarrhythmics is unavailable in most cardiovascular conditions. 
These and other clinical trials and meta-analytic studies indicate that better 
understanding of proarrhythmic events and more effective antiarrhythmics devoid of serious 
side effects are required for prevention of life threatening arrhythmias. 
This thesis summarizes the results of experimental studies, which examined the anti and 
proarrhythmic effects of both novel antiarrhythmic agents and widely used clinical 
antiarrhythmic drugs of three major classes of antiarrhythmics Le. K + channel blockers (Class 
III), Ca 2 + channel blockers (Class IV) and Na+ channel blockers (Class I). 
1.2. Potassium channel blockers 
Repolarization prolonging drugs (Class HI antiarrhythmics) exert their effects mostly 
by blocking K + channels [20]. These agents prolong the atrial and the ventricular action 
potential duration and the corresponding effective refractory period and prevent or terminate 
reentrant ventricular tachycardias (VT) leading to ventricular fibrillation (VF) [21-23]. The use 
of these agents in the therapy, however, may also result in severe proarrhythmia. 
The typical proarrhythmia observed with the use of drugs delaying ventricular 
repolarization is the provocation of polymorphic ventricular tachycardia denoted torsade de 
pointes (TdP) [24]. This arrhythmia can be evoked by various drugs and toxins in man [25, 
26], especially in the presence of predisposing factors like bradycardia, electrolyte 
abnormalities (Le. hypokalemia and hypomagnesemia), prolonged repolarization, depressed left 
ventricular function and/or a history of life threatening arrhythmias [27, 28]. The underlying 
mechanism of this arrhythmia is still not known fully, but early afterdepolarizations (EAD) and 
dispersion of ventricular repolarization are suspected to be the main electrophysiologic 
substrates for TdP generation [28,29]. Initiation of TdP is also usually associated with a pause 
or slowing of heart rate and a concomitant increase in QT interval, followed by a series of 
rapid repetitive polymorphic QRS complexes with characteristic undulating peaks [30, 31]. 
Sometimes TdP can deteriorate into VF, a mechanism undoubtedly responsible for sudden 
cardiac death in a number of patients [32]. 
Quinidine, a combined K + and Na+ channel blocker, was by far the most frequently 
reported drug associated with TdP in the clinical practice [25]. On the contrary, amiodarone a -
combined K+, Na + and Ca 2 + channel blocker with antiadrenerg effects was found to have a 
remarkably low potential for inducing TdP [33, 34]. 
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Almokalant is a novel class III antiarrhythmic agent, which blocks selectively the rapid 
component of the delayed rectifier K + current (IKI) [35]. Clinical studies have already proved 
that almokalant is an effective antiarrhythmic agent in patients with supraventricular 
reciprocating tachycardias [36] and in post-myocardial infarction patients with ventricular 
premature beats (VPB) [37]. On the other hand, almokalant can evoke TdP both in 
experimental animals [38, 39] and in man [40,41]. 
d-Sotalol, another Class III antiarrhythmic agent, inhibits multiple cardiac K + channels 
e.g. IKT, transient outward current (I t o) and inward rectifier current (I K 1) [42]. d-Sotalol has 
been shown to exert antiarrhythmic effects in a number of animal studies [43-45] and in man 
[46, 47]. On the other hand, d-sotalol can evoke TdP both in experimental animals [39, 48] 
and in man [42]. 
Though most of the K + channel blockers possess the described two-faced nature i.e. 
both prevent and induce severe arrhythmias in man, no experimental studies have been 
published in which both the antiarrhythmic and the proarrhythmic effect of these drugs would 
have been examined in the same species under well defined in vivo experimental conditions. 
Although useful canine in vivo experimental arrhythmia [49, 50] and proarrhythmia 
[51, 52] models have been developed, there are some disadvantages of these models e.g. the 
extensive collateral circulation of the canine heart [53] and the high expenses. There have been 
in vivo, experimental arrhythmia [54] and proarrhythmia [55] models developed for the rabbit 
too. The anatomy of the coronary arteries of the rabbit is rather variable, but there is no 
collateral circulation in the rabbit's heart unlike in dog's heart [53], and thus, myocardial 
infarction in the rabbit can mimic better human myocardial infarction. Moreover, rabbit is a 
relatively inexpensive small laboratory animal and its cardiac electrophysiology is reported to 
have similar depolarizing and repolarizing currents to that of man [56, 57]. Though it needs 
skill to perform coronary artery occlusion in the rabbit, the proarrhythmia model [55], unlike in 
the dog [51,52], is quite simple in this species, and does not need difficult surgical techniques. 
Several animal models have been developed with TdP as the endpoint [58-60]. The 
method developed by Carlsson et al. [55] of the acquired long QT syndrome utilizes 
anesthetized rabbits, and TdP is evoked by co-administration of a test agent with the selective 
ai-agonist, methoxamine. Almokalant and d-sotalol are highly proarrhythmic and prone to 
evoke TdP in rabbits [38,48]. 
Although Carlsson's model has been used to examine the proarrhythmic activity of 
novel antiarrhythmic agents [48, 61, 62], the model has not been characterized sufficiently for 
its clinical relevance. Importantly, the information on the effects of long-established drugs with 
clinically well-characterized proarrhythmic activity is sparse. 
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1.3. Calcium channel blockers 
Of the major classes of antiarrhythmic drugs, class IV agents (calcium antagonists) can 
suppress ischemia-induced VF in animal models [63]. (±)-Verapamil possesses selectivity for 
L-channels in ischemic versus (vs.) non-ischemic myocardium, and this is determined in part by 
the facilitatory effect of extracellular K+, which increases in concentration locally during acute 
ischemia [64]. However, (^-verapamil's ischemia-selectivity is inadequate since marked 
atrioventricular (AV) nodal effects and catastrophic hypotension occur at the doses necessary 
for VF suppression [64], which would explain why (±)-verapamil fails to prevent sudden 
cardiac death in man [65]. 
(+)- and (-)-verapamil reduce developed pressure and increase diastolic pressure in 
perfused rat hearts, and this action is enhanced by increasing the K + content of the perfusion 
solution to mimic the rise in K + that occurs in acute ischemia [63, 64]. This negative inotropic 
activity of (+)- and (-)-verapamil is fully attributable to L-type calcium antagonist activity [63]. 
Thus, measuring the effect of a Ca 2 + channel inhibitor on ventricular contractile function during 
varying perfusion K+ content can determine whether the drug has greater or lesser putative 
ischemia-selective L-channel blocking activity than (±)-verapamil, under the assumption that 
the potentiation by K + of effects on contractile function is indicative of a common mechanism, 
namely L-channel blockade. 
Mibefradil is a calcium antagonist that blocks both L and T-channels [66-69]. Although 
it is known that mibefradil can suppress exercise related arrhythmias in dogs with healed 
myocardial infarction [70], it is not known whether the drug can suppress arrhythmias induced 
by sustained acute ischemia, whether it can do so without causing severe AV block or 
vasodilatation, or whether any effects are T or L-channel-mediated. 
1.4. Sodium channel blockers 
Although there is no accurate information on the time-course of susceptibility to VF 
following coronary artery obstruction in man, animal studies show that VF susceptibility has 
two peaks during ischemia, one during the first 30 min (phase-1), and one after 90 min (phase-
2), and another during reperfiision [71, 72]. Each of these, if they occur in man, could 
contribute to sudden cardiac death. 
Class I antiarrhythmic agents block Na+ channels, and can be subdivided into la, lb and 
Ic on the basis of their binding characteristics and selectivity for Na+ vs. K + channels [73]. 
Despite their extensive clinical use, and evidence of suppression of certain types of ventricular 
arrhythmias [74-76], meta-analysis of cumulative data from large numbers of patients showed 
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that these drugs are ineffective in the prevention of sudden cardiac death [65, 77]. 
Furthermore, Class Ic drugs actually increased mortality in patients with coronary artery 
disease [1, 2]. As a consequence of these data and similar data sets for other classes of drugs, 
the consensus is that individual animal models cannot be used alone to predict clinical 
effectiveness against sudden cardiac death in man [78], which means that there is a need for 
more extensive assessment of drugs in a range of animal models. 
The isolated rat heart model with regional ischemia caused by coronary artery 
occlusion allows the generation and examination of ischemia- and reperfusion-induced VF [71, 
79]. Phase-1 VF peaks after 7-15 min of ischemia, and reperfusion causes VF any time 
between 5 and 40 min after the start of ischemia [72, 80]. 
Interestingly, the effects of Na+ channel blockers on phase-1 VF have not been 
examined in the isolated rat heart model [72]. The lack of clinical effectiveness of Class I drugs 
[65, 77] implies that at least one of the forms of VF that contributes to sudden cardiac death in 
man (phase-1, phase-2 or reperfusion-induced) is unaffected (or even exacerbated) by these 
drugs. If this is the case then, at the so-called human 'therapeutic' plasma concentrations, these 
drugs would be expected to fail to prevent phase-1 VF or reperfusion VF in isolated rat hearts. 
1.5. Aims of the study 
The primary goal of the K+ channel blocker study was to examine both the 
antiarrhythmic and the proarrhythmic effect of newly developed K + channel blockers in the 
same species under well defined in vivo experimental conditions. The first set of experiments 
assessed the antiarrhythmic activity of almokalant and d-sotalol against reperfusion induced VF 
in anesthetized rabbits subjected to coronary artery occlusion and reperfusion. In order to 
examine the proarrhythmic profile of almokalant, the effects of continuous almokalant 
infusions were studied in anesthetized rabbits during ai-adrenoceptor stimulation by 
phenylephrine. Another set of experiments examined the proarrhythmic effects of quinidine and 
amiodarone, two widely used antiarrhythmic drugs, and compared them with d-sotalol and 
almokalant in anesthetized rabbits during ai-adrenoceptor stimulation by phenylephrine. 
The aim of the Ca 2 + channel blocker study was to examine whether mibefradil can 
suppress ischemia and reperfusion arrhythmias in a controlled in vitro setting that allows for 
precise determination of concentration response relationships for actions on ventricles, the AV 
node, and coronary vessels. (±)-Verapamil was used as a positive control. If T-channels are a 
more useful target than L-channels, then mibeftadil should be more selective than (±)-
verapamil for suppression of VF. The model chosen was the isolated perfused rat heart 
6 
(Langendorff preparation), which has been shown to detect significant antiarrhythmic effects of 
a variety of agents [72]. Arrhythmia data were contrasted with effects in separate groups of 
hearts on ventricular contractile function, varying perfusion K + content to determine whether 
mibefradil has greater or lesser putative ischemia-selective L-channel blocking activity than 
(±)-verapamil. 
In the sodium channel study a set of experiments examined the antifibrillatory effect of 
representative Class la, lb and Ic drugs, (quinidine, lidocaine and flecainide) each at two 
concentrations equivalent to the clinically relevant 'therapeutic' unbound and total plasma 
concentrations in isolated Langendorff perfused rat hearts. In order to detect antifibrillatory 
effects, the perfusion solutions contained 3 mM K+, which allows high incidence of VF in 
controls [71, 79]. Additionally, a limited number of experiments was performed to examine the 
proarrhythmic effects of the three drugs using perfusion solutions containing 5 mM K+, which 
give rise to a low incidence of ischemic VF in control hearts [79] and hence scope to reveal 
proarrhythmia. 
2. MATERIALS AND METHODS 
2.1. Animals 
The anti- and proarrhythmic activity of K+ channel inhibitors were examined in vivo in 
New Zealand White rabbits from either sex weighing 1.5-3.0 kg. In vitro investigations were 
performed on hearts excised from male Wistar rats weighing 180-250 g to assess the anti- and 
proarrhythmic activity of Ca 2 + and Na+ channel inhibitors. 
2.2. Examination of the anti- and proarrhythmic activity of K* channel inhibitors in vivo 
2.2.1. Myocardial ischemia and reperfusion in anesthetized rabbits 
Acute coronary artery occlusion and reperfusion were performed as described by Coker 
[54]. Rabbits (n=87) were anesthetized with pentobarbital-Na (30 mg kg'1 i.v.). A catheter was 
introduced into the right carotid artery in order to measure blood pressure (Blood Pressure 
Monitor BP-1, World Precision Instruments, Berlin, Germany). The catheter was filled with 
isotonic saline containing heparin-Na (500 I.U. ml'1), but the animals were not heparinized. 
Another catheter was introduced into the marginal vein of the left ear for infusion of drugs. 
After tracheal cannulation, left thoracotomy was performed and artificial ventilation 
was immediately started with room air (Harvard rodent ventilator, model 683, Harvard 
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Apparatus, South Natick, MA, USA) with a respiratory volume and rate of 7 ml kg"1 per 
stroke and 40 stroke min"1, respectively. 
After pericardiotomy, a loose loop of 4-0 atraumatic silk (Ethicon, Edinburgh, UK) 
was placed around the first branch of the left circumflex coronary artery just under its origin. 
Both ends of the ligature were led out of the thoracic cavity through a flexible tube. Tightening 
the loose loop with a clamp fixed on the silk induced regional ischemia. Releasing the occluder 
induced reperfusion. 
The electrocardiogram (lead I, II, III) was registered during the experiments by a 
thermographic recorder (ESC 110 4 CH, Multiline KFT, Esztergom, Hungary) using 
subcutaneous needle electrodes. 
2.2.2. Experimental protocol of the rabbit ischemia-reperfusion experiments 
In the first set of experiments isotonic saline or almokalant (35 or 88 pg kg'1) was 
administered intravenously over 10 min in continuous infusion in a volume of 2 ml right before 
the coronary artery occlusion. 
In the second set of experiments saline or d-sotalol (1 or 3 mg kg'1) was administered 
intravenously with a short infusion over 1 min in a volume of 2 ml kg'1 5 min prior to coronary 
artery occlusion. 
After drug treatment coronary artery was occluded to achieve myocardial ischemia for 
10 min. At the end of ischemia the ligature was released and 10 min of reperfusion followed. 
2.2.3. Occluded zone size and exclusion criteria in anesthetized rabbits 
At the end of reperfusion, heparin-Na (500 U.I. kg*1, i.v.) was administered and the 
animals were killed with an overdose of pentobarbital-Na. The hearts were excised and the size 
of the occluded zone (the region subjected to ischemia and reperfusion) was quantified using 
the ethanol exclusion method [81] and expressed as per cent total ventricular weight. All 
rabbits with an occluded zone less than 16% or larger than 32% were excluded from the final 
evaluation. 
2.2.4. Preparation of anesthetized rabbits for the proarrhythmia experiments 
The proarrhythmic activity of K+ channel inhibitors was examined in an animal model of 
acquired long QT syndrome [55]. After sedation with pentobarbital-Na (5 mg kg"1, i.v.), male 
rabbits (n=76) were anesthetized with a-chloralose (100 mg kg"1, i.v.). 
Catheters were introduced into the right carotid artery, the right jugular vein and the 
marginal vein of the left ear for recording arterial blood pressure and infusion of drugs, 
respectively. After tracheal cannulation, the animals were mechanically ventilated with room 
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air as described in section 2.2.1. Blood pressure and electrocardiogram (ECG) were registered 
during the experiments as in the occlusion-reperfusion model. 
2.2.5. Experimental protocol of the rabbit proarrhythmia experiments 
In the first set of proarrhythmia experiments continuous i.v. phenylephrine infusion, at 
the rate of 15 pg kg'1 min1, was administered for 80 min. Ten min after beginning of 
phenylephrine infusion, simultaneous and continuous i.v. almokalant infusion was given at the 
rate of 8.8 or 26 pg kg"1 min'1 for 70 min. Equivalent volume of isotonic saline was 
administered to the animals in the control group instead of almokalant. The infusion rates were 
chosen to administer the antiarrhythmic dose of almokalant (88 pg kg'1) at the slow infusion 
rate over 10 min and at the high infiision rate over 3.33 min. 
In the second set of proarrhythmia experiments continuous i.v. phenylephrine infiision, 
at the rate of 15 pg kg'1 min'1, was begun, and was continued for 85 min. Ten min after the 
beginning of phenylephrine infusion, increasing doses of almokalant (26, 88, 260 pg kg'1), d-
sotalol, quinidine, amiodarone (3, 10, 30 mg kg'1) or isotonic saline were administered 
intravenously. Each dose was given over a period of 5 min and there was 20 min interval 
between each dose of antiarrhythmic. The doses were chosen to span the antiarrhythmic dose 
range used by our group (see section 2.2.2.) and others [82-84]. 
2.2.6. Arrhythmia diagnosis and ECG analysis in the rabbit in vivo experiments 
From the ECG, the incidence, the time to onset and the duration of ventricular 
arrhythmias were obtained. Ventricular premature beats (VPB), bigeminy, salvo and 
ventricular fibrillation (VF) were defined in accordance with the definitions of the Lambeth 
Convention [85]. When continuous VF lasted longer than 120 s then VF was defined as 
sustained VF. Torsade de pointes (TdP) was defined as an arrhythmia in which five or more 
repetitive VPB were coupled, and for which the QRS complex showed a cyclic variation in 
size and shape. Every run of 4 VPB with twisting QRS morphology and every run of 4 or 
more VPB without the torsade-like twisting QRS morphology were differentiated from TdP 
and were defined as ventricular tachycardia (VT). Blocks in the conduction system were also 
monitored. Conduction disturbances included atrioventricular (AV) blocks and intraventricular 
conduction defects (right or left bundle branch block). 
Blood pressure, PP, RR and QT intervals were also measured at predetermined 
intervals. These parameters were also measured at the first incidence of TdP in the 
proarrhythmia experiments. In the second proarrhythmia study, where the proarrhythmic 
effects of d-sotalol, almokalant, quinidine and amiodarone were compared, 2:1 AV block 
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occurred frequently in some drug treated groups, therefore both sinus rate (SR=60/PP) and 
ventricular rate (VR=60/RR) were calculated subsequently instead of calculating a single heart 
rate value. Rate corrected QT interval (QTc) was calculated subsequently by using both 
Carlsson's equation [38]: QTc(Carlsson)=QT-0.175(RR-300) and Bazett's formula: 
QTc(Bazett)=QT/square root RR. 
2.2.7. Drugs in the rabbit in vivo experiments 
The following drugs were used: almokalant (AstraZeneca, Molndal, Sweden), d-sotalol 
(Bristol-Myers Squibb, Wallingford, CT, USA), quinidine (Alkaloida, Tiszavasvari, Hungary), 
amiodarone (Cordarone injection, Sanofi Pharma, France), phenylephrine (L-Phenylephrine 
HC1, Koch-Light Laboratories LTD, Colnbrook-Bucks, England). Almokalant was prepared as 
a concentrated stock solution (35 mg ml'1) by AstraZeneca. The stock solution was diluted 
further with isotonic saline (saline). d-Sotalol and quinidine were dissolved also in saline. 
Amiodarone was prepared by diluting Cordarone injection (150 mg amiodarone in 3 ml) with 
saline. Each solution was prepared on the day of the experiment. 
2.3. Assessment of the anti- and proarrhythmic effects of Na* and Ca 2 + channel blockers 
in vitro 
2.3.1. Myocardial ischemia and reper fusion in isolated rat hearts 
Rats were anesthetized with pentobarbital-Na (60 mg kg'1 i.p.) mixed with 250 I.U. 
heparin-Na to prevent blood clot formation in the coronary vasculature. Hearts were excised 
and placed into ice-cold solution containing (in mM), NaCl 118.5, NaHCC>3 25.0, MgSC>4 1.2, 
NaH2P04 1.2, CaCl2 1.4, KC1 3 (or 5 where indicated) and glucose 11.1, then perfused 
according to Langendorff, with solution delivered at 37°C and pH 7.4. Perfusion pressure was 
maintained constant at 70 mmHg. A unipolar ECG was recorded by implanting one stainless-
steel wire electrode into the center of the region to become ischemic with a second connected 
to the aorta. A traction-type coronary occluder consisting of a silk suture (Mersilk, 4/0) 
threaded through a polythene guide was used for coronary occlusion. The suture was 
positioned loosely around the left main coronary artery. Regional ischemia and reperfusion 
were induced by tightening the occluder and by releasing it. 
2.3.2. Experimental protocol of the sodium channel inhibitor study 
Four sets of experiments were performed and each of them consisted of four groups 
(quinidine, lidocaine, flecainide or vehicle control). In the first set of experiments hearts were 
perfused with the lower concentrations of the drugs, i.e. quinidine 0.79 pM, lidocaine 3.88 
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JJM, flecainide 0.74 pM or vehicle (time-matched control). In the second set of experiments 
hearts were perfused with the higher concentrations of the drugs, i.e. quinidine 7.90 pM, 
lidocaine 12.93 pM, flecainide 1.48 pM or vehicle (time-matched control). In these first two 
sets of experiments all perfusates were prepared by using modified Krebs' solution containing 
3 mM K + , and each group consisted of n=12 hearts. In the third and fourth sets of experiments 
again the same lower and higher drug concentrations were used, together with vehicle 
controls, but the Krebs' solution was modified to contain 5 mM K + , and each group consisted 
of n=6 hearts. 
In all four sets of experiments hearts were perfused for an initial 5 min with control 
solution, then solution was switched to one of the four test solutions: control (vehicle), 
quinidine, lidocaine or flecainide. After a further 5 min perfusion, the left main coronary artery 
was occluded. After 30 min of ischemia the occluder was released to achieve reperfusion. 
Individual measures of coronary flow, and ECG variables were taken at predetermined 
intervals. 
The choice of drug concentrations was based on the following. In clinical studies aimed 
at evaluating drug effects on ventricular arrhythmias, peak blood concentrations (unbound 
fraction plus plasma-protein bound fraction) have been determined following typical drug 
dosage. These concentrations have been reported to be 7.90 pM for quinidine [76], 12.93 pM 
for lidocaine [74] and 1.48 pM for flecainide [75]. These concentrations are within the so-
called human therapeutic range for these agents [86]. All three drugs are plasma protein 
bound: quinidine 90%, lidocaine 70% and flecainide 50% [87]. Thus, the plasma-protein 
unbound concentrations associated with these clinically relevant dosage are approximately 0.79 
pM, 3.88 pM and 0.74 pM for quinidine, lidocaine and flecainide, respectively. Therefore we 
chose to study the mean peak unbound and mean peak total plasma concentrations (lower and 
higher concentrations, respectively). 
2.3.3. Experimental protocol of the calcium channel inhibitor study 
Hearts (n=12/group) were perfused for an initial 5 min with control solution, then 
solution was switched to one of 11 solutions: control (vehicle), 10, 30, 100, 300 or 600 hM 
mibefradil or 10, 30, 100, 300 and 600 nM (±)-verapamil. After a further 5 min perfusion, the 
left coronary artery was occluded. After 30 min ischemia the occluder was released to achieve 
reperfusion. Individual measures of coronary flow, and ECG variables were taken at 
predetermined intervals. 
11 
The choice of drug concentrations was based on the following. Both (±)-verapamil and 
mibefradil are highly plasma protein bound: >80% [88] and more than 99% (Clozel, personal 
communication) respectively. The unbound plasma concentration of (±)-verapamil associated 
with a 50% reduction in severity of ischemia-induced arrhythmias in conscious rats is 600 nM 
[88]. Therefore, the initial plan was to study a range of concentrations of (±)-verapamil with 
600 nM as the median. However, we found in preliminary studies that 600 nM (±)-verapamil 
reduced developed pressure in rat hearts by more than 50 %, and caused AV block in some of 
the hearts. In contrast, in conscious rats mean blood pressure was reduced by less than 50 %, 
and AV block did not occur when unbound blood levels were -600 nM [88]. The explanation 
for this discrepancy is likely to be that the potency of (±)-verapamil increases when 
sympathetic tone is removed [89], i.e., by cardiac excision. Thus, 600 nM was chosen as the 
maximum (±)-verapamil concentration for the present experiments. This is sufficient to cause 
L-channel blockade in isolated ventricular myocytes [90]. 
For mibefradil, the mean plasma concentration in man following a 100 mg p.o. dose is 
870-1200 nM (Clozel personal communication; Welker personal communication). This means 
that mean unbound concentrations are in the region of 10 nM. In order to ensure that 
mibefradil and (±)-verapamil could be contrasted at identical concentrations, and taking these 
other factors into consideration, we opted to test 10, 30,100, 300 and 600 nM of each drug. 
2.3.4. Occluded zone size, coronary flow and exclusion criteria in isolated rat hearts 
At the end of five minutes of reperfusion the size of the occluded zone was quantified 
using the disulphine blue dye exclusion method [71] and expressed as per cent total ventricular 
weight. Coronary flow was measured by timed collection of coronary effluent. 
Any heart with a sinus rate less than 250 min"1, or a coronary flow more than 23 ml 
min1 g"1 or less than 7.5 ml min'1 g"1 6 min before the onset of ischemia (before the start of 
perfusion with drug or vehicle) or an occluded zone of less than 30% or more than 50% of 
total ventricular weight was excluded. All excluded hearts were replaced to maintain equal 
group sizes. Any heart not in sinus rhythm during the 2 s before the start of reperfusion was 
excluded from the reperfusion sample, but was not replaced. For this reason, incidences of 
reperfusion-induced arrhythmias are assessed for groups of sizes that are may not be equal. 
2.3.5. Arrhythmia diagnosis and ECG analysis in the isolated rat heart studies 
The ECG was recorded using a MacLab system. Arrhythmias were defined according 
to the Lambeth Conventions [85]. From the ECG, the incidence and the time to onset of 
ventricular tachyarrhythmias, the PR interval, RR interval and the QT interval (measured at the 
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point of 90% repolarization with on-screen cursors) were obtained. QT interval was not 
corrected for heart rate as it is not rate-dependent in perfused rat hearts [91]. 
2.3.6. Assessment of ischemia-selective L-channel blocking activity of Ccf* antagonists 
Isolated rat hearts (n=10/group) were perfused with standard solution (see above) 
containing 3, 6 or 10 mM K+, and a compliant non-elastic balloon [92] was inflated in the 
ventricle so as to give a developed pressure of more than 100 mmHg at a diastolic pressure of 
less than 5 mmHg. To standardize the experiment, the balloon was inflated with an added 
volume of 0.12 ml, which obtains a developed pressure under baseline conditions of about 70 
% of the maximum achievable in a heart weighing 0.6-0.7 g [93]. 
The hearts were initially perfused for 15 min with drug-free solution, then exposed to 
30, 100, 300 and 600 nM mibefradil or (±)-verapamil, sequentially, 5 min per concentration. 
Exposure was continuous, and separate perfusion reservoirs were used for each solution. 
Preliminary studies established that this was ample time for drug effects to peak. Separate 
hearts were used for each drug. A time-matched control group was used for each K+ 
concentration. In these controls the perfusion delivery was switched every 5 min between 
reservoirs each containing drug vehicle solution. 
Variables (diastolic pressure, developed pressure and coronary flow) were recorded 1 
min before exposure to each concentration of drug and 4 min after introduction of the highest 
concentration of drug. 
2.3.7. Drugs in the isolated rat heart studies 
All salts were reagent grade chemicals from Sigma Chemical Co. Drug stocks of Na+ 
and Ca2 + channel inhibitors were prepared fresh each week and perfusion solutions were 
prepared fresh each day. 
2.4. Statistical evaluation of the results of the in vivo and in vitro studies 
The percentage incidence of arrhythmias was calculated and compared by using 
Fisher's exact probability test. Continuous data were expressed as mean ± standard error of the 
mean (S.E.M.). Gaussian distributed variables from the same sample were compared with 
Student's paired-samples "t" test. Gaussian distributed variables from independent samples 
were compared with one way analysis of variance followed by multiple comparisons according 
to the "Least Significant Difference" method or Dunnett's test when appropriate. Comparisons 
within group were made using Wilcoxon's signed ranks test and comparisons between groups 
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were made using Kruskal-Wallis test on any data that was not normally distributed. Differences 
were considered statistically significant when P<0.05. 
3. RESULTS 
3.1. Examination of the antiarrhythmic activity of potassium channel blockers 
3.1.1. Effect of almokalant and d-sotalol on the ischemic and reperfusion arrhythmias 
None of the drug infusions evoked arrhythmias before coronary artery occlusion. 
During ischemia the incidence of VF was not statistically different in the almokalant- or d-
sotalol-treated animals from the appropriate control groups (Table 1). There were no 
significant differences between the treated and control groups with respect to the incidence of 
other types of arrhythmias during 10 min of ischemia (Table 1). 
Table 1. Effect of almokalant and d-sotalol on the survival rate and incidence of arrhythmias 
during ischemia and reperfusion in anesthetized rabbits 
Incidence of arrhythmias (%) 
Dose n Survived (%) None VF VT Other 
Ischemia 
Control 0 fig kg"1 15 80 47 27 0 47 
Almokalant 35 fig kg 1 13 100 69 8 0 31 
Almokalant 88 fig kg'1 14 100 71 0 0 29 
Control 0 mg kg'1 19 58 21 42 11 74 
d-Sotalol l.Omgkg 1 13 92 38 8 0 62 
d-Sotalol 3.0 mg kg"1 13 92 54 8 0 46 
Reperfusion 
Control 0 fig kg"1 12 42 8 75 42 58 
Almokalant 35 fig kg 1 13 62 31 39 31 46 
Almokalant 88 fig kg"1 14 86* 43 21* 14 57 
Control 0 mg kg"1 11 18 0 82 64 46 
d-Sotalol 1.0 mg kg'1 12 75* 33 25* 33 67 
d-Sotalol 3.0 mg kg"1 12 83* 33 17* 33 75 
n, number of animals; VF, ventricular fibrillation; VT, ventricular tachycardia; Other, 
ventricular premature beat, salvo, and/or bigeminy; *P<0.05 vs. control. 
Almokalant in a dose of 88 pg kg"1 and d-sotalol (1 and 3 mg kg"1) significantly 
reduced the incidence of reperfusion-induced VF (Table 1) and increased the number of 
animals surviving reperfusion (Table 1). There were no differences in the incidence of other 
types of arrhythmias between drug treated and control rabbits during reperfusion (Table 1). 
14 
3.1.2. Effect of almokalant and d-sotalol on the blood pressure, heart rate and QTc intervals 
Almokalant and d-sotalol pretreatment had no effect on the blood pressure (Table 2). 
However, mean arterial blood pressure fell significantly in all groups due to coronary artery 
occlusion as compared to pre-occlusion values (77±3 vs. 86±3 mmHg, 83±3 vs. 90±3 mmHg, 
74±5 vs. 88±4 mmHg in controls, 35 and 88 pg kg'1 almokalant treated animals, respectively, 
and 74±4 vs. 100±3 mmHg, 78±5 vs. 97±3 mmHg, 84±3 vs. 100±3 mmHg in controls, 1 and 3 
mg kg"1 d-sotalol-treated animals, respectively, all P<0.05). 
Table 2. Effect of almokalant and d-sotalol on the mean arterial blood pressure, heart 
rate, QT and QTc intervals in anesthetized rabbits 
Dose n Before drug Pre-occlusion 
Control 0 pg kg'1 15 MBP 86±3 86±3 
HR 288±7 288±7 
QTc 163±3 163±4 
Almokalant 35 pg kg"1 13 MBP 89±3 90±3 
HR 278±9 282±7 
QTc 165±6 167±6 
Almokalant 88 ug kg"1 14 MBP 88±3 88±4 HR 280±7 270±6# 
QTc 159±4 175±6# 
Control 0 mg kg'1 19 MBP 101±3 100±3 HR 271±7 268±7 
QTc 162±3 162±4 
d-Sotalol 1.0 mg kg'1 13 MBP 97±3 97±3 HR 272±9 252±9# 
QTc 156±4 172±4# 
d-Sotalol 3.0 mg kg"1 13 MBP 95±4 100±3 HR 265±10 247±8# 
QTc 163±6 176±6# 
n, number of animals; MBP, mean arterial blood pressure (mmHg); HR, heart rate 
(min1); QTc, Carlsson's rate corrected QT interval (ms); #P<0.05 vs. the preinfusion 
value of the same group 
Almokalant in a dose of 88 pg kg'1 and d-sotalol (1 and 3 mg kg'1) significantly 
decreased the heart rate of rabbits compared to the basal values (Table 2). Coronary occlusion 
did not change heart rate significantly compared to pre-occlusion values. No significant 
changes occurred in the heart rate of animals during reperfusion. 
Almokalant in a dose of 88 pg kg'1 and d-sotalol (1 and 3 mg kg'1) significantly 
lengthened QTc intervals (Table 2). No significant changes occurred in the QTc intervals 
during reperfusion. 
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3.2. Examination of the proarrhvthmic profile of a selective potassium channel blocker 
3.2.1. Effects of phenylephrine before almokalant infusions 
In the first 10 min, when only phenylephrine was administered to every animal, the 
heart rate decreased, the mean arterial blood pressure increased and the QTc intervals were 
prolonged significantly in all three groups (Table 3). Every animal survived this period, but 
only 26% (8 out of 31) of them had no any arrhythmia. VPB, bigeminy and salvo appeared in 
55% (17 out of 31) of the animals. TdP, VT or VF did not occur in this period. 
3.2.2. Effect of almokalant infusions on the blood pressure, heart rate and QTc interval 
In both almokalant treated groups the heart rate values were statistically not different 
from those in the control group. In contrast, the blood pressure was significantly lower in the 
80th min in the group of animals treated with almokalant infusion at the rate of 8.8 pg kg'1 
min'1 and from the 20th min in the group of animals treated with almokalant infusion at the rate 
of 26 pg kg"1 min"1, as compared to the control group (Table 3). 
Table 3. The effect of continuous almokalant infusions on the heart rate, blood pressure and 
the rate corrected QT intervals in anesthetized rabbits primed with phenylephrine 
n Basal 
Phe Phe + drug 
10 min 20 min 30 min 40 min 50 min 60 min 70 min 80 min 
Control 
HR 10 284±11 217±8# 192±10 195±9 192±11 190±12 192±12 188±14 184±15 
MBP 87±4 120±3# 117±3 118±2 118±2 116±2 116±3 118±3 117±3 
QTc 154±5 176±3# 180±4 181±3 185±4 183±4 184±5 181±5 180±6 
Aim 8.8 
HR 10 289±11 219±16# 209±16 213±16 203±14 211±11 218±10 212±13 220±14 
MBP 98±3 117±3# 117±3 114±3 109±4 106±5 105±5 106±4 80±6* 
QTc 155±3 177±7# 196±4 192±4 202±5* 215±8"' 202±6 198±6 191±13 
Aim 26 
HR 11 289±10 204±15# 186±14 182±12 193±16 197±14 196±16 198±13 222±15 
MBP 93±4 108±3# 98±6* 94±5* 92±4* 87±6* 87±6* 82±6* 77±3* 
QTc 163±4 185±6# 228±8*f 228±9*t 238±10*1 h 230±10* 223±7*t 215±7* 216±10* 
Control, time matched control (0 pg kg'1 min'1) group; Aim 8.8 and Aim 26, groups of animals 
treated with almokalant infusion at the rate of 8.8 or 26 pg kg'1 min'1; HR, heart rate (min1); 
MBP, mean arterial blood pressure (mmHg); QTc, Carlsson's rate corrected QT interval (ms); 
n, number of animals; Phe, phenylephrine infusion at the rate of 15 pg kg"1 min'1; #P<0.05 vs. 
basal value; *P<0.05 vs. control group; fP<0.05 vs. the QTc of Aim 8.8 group. 
Saline infusion did not add to the QTc widening caused by phenylephrine (Table 3). 
However, almokalant infusion produced a dose related further prolongation of the QTc 
interval compared to the control group (Table 3). 
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3.2.3. Incidence of arrhythmias evoked bv continuous almokalant infusions 
In the control group, after the first 10 min, when saline was administered 
simultaneously with phenylephrine, only VPB, trigeminy and salvos occurred and none of the 
animals died, whereas in the groups of animals treated with almokalant simultaneously with 
phenylephrine even TdP, VT (different from TdP) and VF appeared (Table 4). The incidence 
of TdP was significantly higher in the group of animals treated with almokalant infusion at the 
rate of 26 pg kg"1 min'1. TdP usually ended spontaneously after several seconds. Sometimes 
monomorphic VT and TdP were attached for a short period or transformed into each other 
continuously for a longer time. There was one animal treated with almokalant at lower infusion 
rate in which only monomorphic VT developed as a malignant ventricular arrhythmia and TdP 
did not. One animal died in both almokalant treated groups due to deterioration of TdP into 
sustained VF (Table 4). 
Table 4. The effect of continuous almokalant infusions on the survival rate and incidence of 
arrhythmias in anesthetized rabbits primed with phenylephrine 
n Survived (%) None 
Incidence of arrhythmias (%) 
VF VT TdP Other 
Control (0 pg kg'1 min'1) 10 100 10 0 0 0 60 
Almokalant 8.8 pg kg'1 min'1 10 90 10 10 10 20 80 
Almokalant 26 pg kg'1 min'1 11 91 0 18 18 73* 91 
n, number of animals; VF, ventricular fibrillation; VT, ventricular tachycardia; TdP, torsade de 
pointes; Other, ventricular premature beat, salvo, and/or bigeminy; *P<0.05 vs. either control 
group or the group treated with the low infusion rate of almokalant (8.8 pg kg"1 min"1). 
3.3. Comparison the proarrhythmic effects of different potassium channel inhibitors 
The effect of the first 10 min of phenylephrine infusion was qualitatively and 
quantitatively nearly identical to that seen in the first proarrhythmia study (section 3.2.1), thus 
numerical data of this period is not detailed again. 
3.3.1. Incidences of arrhythmias evoked by potassium channel inhibitors and onset times 
Two animals died from sustained VF due to administration of antiarrhythmic drugs. 
One of them died after administration of 88 pg kg'1 almokalant and the other one died after 
administration of 30 mg kg"1 d-sotalol (Table 5). Quinidine 30 mg kg"1 induced VT in 2 out of 
7 animals. However, this drug did not cause TdP. VT was also induced by 10 and 30 mg kg'1 
of d-sotalol and each dose of almokalant (Table 5). TdP was evoked only by d-sotalol and 
almokalant. The 2nd and 3rd doses of d-sotalol (10 and 30 mg kg'1) significantly increased the 
cumulative incidence of less complex arrhythmias (i.e. VPB, bigeminy and salvo) and the 
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incidence of VT and evoked TdP in 60% of animals (Table 5). Likewise, the 2nd and 3rd doses 
of almokalant increased significantly the cumulative incidence of less complex arrhythmias and 
the incidence of VT and all three doses induced TdP (Table 5). Quinidine, d-sotalol and 
almokalant evoked conduction blocks in a dose related manner, whereas blocks never occurred 
after amiodarone and saline administration (Table 5). 
Table 5. The incidence of arrhythmias in phenylephrine primed 
anesthetized rabbits treated with d-sotalol, almokalant, quinidine 
or amiodarone 
Incidence of arrhythmias (%) 
n SVF VF TdP VT Block Others 
Control 
1st 10 0 0 0 0 0 60 
2nd 10 0 0 0 0 0 10 
3rd 10 0 0 0 0 0 20 
total 10 0 0 0 0 0 60 
d-Sotalol 
3 mg kg"1 10 0 0 0 0 0 80 
lOmgkg'1 10 0 0 50* 60* 50* 90* 
30 mg kg'1 10 10 10 40 60* 100* 90* 
total 10 10 10 60* 70* 100* 100 
Almokalant 
26 fig kg"1 10 0 0 20 40 10 80 
88 fig kg"1 10 10 10 40 60* 40 80* 
260 fig kg"1 9 0 0 33 67* 78* 100* 
total 10 10 10 40 70* 70* 100 
Quinidine 
3 mg kg"1 7 0 0 0 0 0 43 
lOmgkg*1 7 0 0 0 0 43 29 
30 mg kg"1 7 0 0 0 29 86* 71 
total 7 0 0 0 29 86* 86 
Amiodarone 
3 mg kg'1 8 0 0 0 0 0 38 
10 mg kg'1 8 0 0 0 0 0 25 
30 mg kg"1 8 0 0 0 0 0 13 
total 8 0 0 0 0 0 38 
n, number of animals; SVF, sustained ventricular fibrillation; VF, 
ventricular fibrillation; TdP, torsade de pointes; VT, ventricular 
tachycardia; Block, conduction block; Others, ventricular 
premature beat, bigeminy and salvo; Control, isotonic NaCl; total, 
the cumulative incidence of arrhythmias in the given group. The 
values in the rows of doses show the incidences of arrhythmias 
dining the administration of the given dose and the subsequent 20 
min interval. *P<0.05 vs. control. 
There was no 
direct correlation 
between the occurrence 
of TdP and the infusion 
rate or the dose of d-
sotalol and almokalant, 
since the percentage 
incidences of this 
arrhythmia were 
greatest after the 
administration of the 
second doses of the 
drugs (Table 5). 
There was a 
significant difference 
between d-sotalol and 
almokalant in terms of 
ventricular 
tachyarrhythmia i.e. VT 
and TdP onset. 
Almokalant induced 
ventricular 
tachyarrhythmias 
shortly after the start of 
the administration of its 
2nd dose (Logio onset 
time 2.206±0.089 s, n=6). In contrast, several minutes delay occurred before the onset of 
ventricular tachyarrhythmias after the start of the administration of the 2nd dose of d-sotalol 
(Logio onset time 2.816±0.084 s, n=6; P<0.05 vs. almokalant). 
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3.3.2. Effect of potassium channel inhibitors on the blood pressure and heart rate 
When saline infusion was begun (control group) during continuous phenylephrine 
infusion, the blood pressure and the heart rate (both sinus and ventricular) did not change 
further (Table 6). 
Addition of d-sotalol reduced blood pressure and ventricular rate dose relatedly (Table 
6). There was dissociation between sinus and ventricular rate after administration of 30 mg kg' 
1 d-sotalol due to frequent occurrence of 2:1 AV block. 
Table 6. Effect of d-sotalol, almokalant, quinidine and amiodarone treatment on the sinus rate, 
ventricular rate and the blood pressure in anesthetized rabbits primed with phenylephrine 
1st dose 2nd dose 3rd dose 
75 min n 0 min 5 min 25 min 30 min 50 min 55 min 
Control 
SR 226411 21449 200±9 19949 200410 200410 202410 
VR 10 226±11 214±9 200±9 19949 200410 200410 202±10 
MBP 12343 12244 12143 12143 11943 12143 11943 
d-Sotalol 
SR 240413 212410« 213±11 19248« 208412 200414 220419 
VR 10 240413 212410« 213411 19248« 208412 17646« 18148 
MBP 122±3 123±3* 12042 107±4«** 11442* 10144«** 11045* 
Almokalant 
235415 : 234411* SR 227±9 238±10 220412 22745 ** 250413* 
VR 10 227±9 219416 220412 195415 22745* 202418 203418 
MBP 12143 11743* 12044 10942** 11444* 10444 ** 10744* 
Quinidine 
SR 211418 240414« 215414 225414 219416 242423 263413 * 
VR 7 211±18 240414« 215414 225414 219416 147431* 177431 
MBP 124±3 9142«* 11743 5942«* 96±4* 3945«* 7643* 
Amiodarone 
SR 227±11 224±11 202420 19749 159410* 16448* 149410* 
VR 8 227±11 224±11 202420 19749 159410* 16448* 149410 
MBP 123±2 113±3«** 12143 9145«** 11644* 7945«** 10746* 
SR, sinus rate (min*1); VR, ventricular rate (min1); MBP, mean arterial blood pressure 
(mmHg); #P<0.05 vs. the value measured right before the beginning of the administration of 
the given dose; *P<0.05 vs. control group; tP<0.05 vs. quinidine MBP; JP<0.05 almokalant 
vs. d-sotalol. 1st dose: 3 mg kg"1 (d-sotalol, quinidine, amiodarone) or 26 pg kg'1 (almoikalant) 
i.v.; 2nd dose: 10 mg kg'1 (d-sotalol, quinidine, amiodarone) or 88 pg kg'1 (almokalant) i.v.; 
3rd dose: 30 mg kg'1 (d-sotalol, quinidine, amiodarone) or 260 pg kg'1 (almokalant) i.v.; 
Control: isotonic NaCl. 
Similarly to d-sotalol, almokalant reduced blood pressure and there was dissociation 
between sinus and ventricular rate after administration of each dose of the drug due to frequent 
2:1 AV blocks (Table 6). Five min after administration of 88 and 260 pg kg'1 almokalant sinus 
rate increased significantly compared to saline control (232±9 vs. 196±9 min'1 and 240±12 vs. 
188±14 min'1, respectively). These differences remained significant till the end of the 20 min 
drug free intervals (Table 6). After the administration of the 2nd dose of almokalant, sinus rate 
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was also significantly different from those after the administration of the 2nd dose of d-sotalol 
(Table 6). This difference remained significant between d-sotalol and almokalant nearly by the 
end of the experiment. On the other hand, there was no significant difference between the 
effect of almokalant and d-sotalol on the blood pressure and ventricular rate during the whole 
experiment. 
The blood pressure drop after each dose of quinidine was significantly greater than 
those at the same time-points in all other groups (Table 6). The 1st dose of quinidine (3 mg kg' 
') elevated heart rate, whereas the 3rd dose (30 mg kg"1) caused 2:1 (and total) AV blocks 
allowing dissociation of sinus and ventricular rates after which sinus rate increased and 
ventricular rate decreased significantly compared to control (Table 6). 
Amiodarone lowered blood pressure in a dose-related maimer. Ten min after 
administration of 10 mg kg'1 amiodarone, heart rate (both sinus and ventricular rate) decreased 
significantly compared to saline control (170±9 vs. 197±9 min"1). From this time-point heart 
rate decreased constantly in amiodarone treated animals and remained significantly different 
from control till the end of the experiment (Table 6). 
3.3.3. Effect of potassium channel inhibitors on the QT and QTc intervals 
Saline infusion had no significant effect on the QT and QTc widening effect of the 
maintained infusion of phenylephrine (Table 7). Amiodarone did not add to the QT and QTc 
widening caused by phenylephrine. However, d-sotalol and almokalant increased the QT and 
QTc in a dose related manner (Table 7) and there was no difference between the time course 
of QT and QTc prolonging effects of the two drugs. Interestingly, only the 3rd dose of 
quinidine (30 mg kg"1) prolonged QT, whereas the rate corrected QT intervals were already 
widened by the 1st dose of the drug (3 mg kg"1) (Table 7). The 2nd dose of d-sotalol and 
almokalant (10 mg kg'1 and 88 pg kg'1, respectively) widened QT and QTc to such an extent 
that these were significantly different from those after administration of the 2nd dose of 
quinidine and amiodarone (10 mg kg'^fTable 7). 
3.3.4. Variables measured before TdP occurrence 
Since there was no statistical difference between the d-sotalol and almokalant treated 
animals in terms of blood pressure, ventricular rate, QT and QTc, these data of the animals 
with TdP induced by either d-sotalol or almokalant were summarized. The values measured 
before the first TdP at the last sinus-origin beats were compared to those measured before 
phenylephrine was begun. In animals with TdP (n=10) mean arterial blood pressure was 
elevated (120±3 vs. 85±2 mmHg at baseline, P<0.05) and ventricular rate was reduced 
(183±13 vs. 286±9 min'1, P<0.05) at the first incidence of TdP. Furthermore, QT and the rate 
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corrected QT intervals were prolonged markedly at this time (QT 262±8 vs. 162±5 ms at 
baseline, QTc-Carlsson 255±8 vs. 178±4 ms, QTc-Bazett 453±15 vs. 353±8 ms, all P<0.05). 
Table 7. Effect of d-sotalol, almokalant, quinidine and amiodarone treatment on the QT and 
the rate corrected QT intervals in anesthetized rabbits primed with phenylephrine 
n 
1st < iose 2nd dose 3rd dose 
75 min Omin 5 min 25 min 30 min 50 min 55 min 
Control 
QT 188±6 19448 2104:10 216412 215412 212411 219413 
QTc (C) 10 193±4 19747 209t8 21449 21349 21149 218410 
QTc(B) 36248 364411 3784:11 387412 386412 382412 397413 
d-Sotalol 
26048 ** f QT 171±5 22349* 2234=9 244413 26149* 266411 
QTc (C) 10 178±4 22548** 2254:7 25746 **f 245411 25349* 260412 
QTc(B) 339±7 415412** 4154:8 46148 *** 450415* 447417* 461421 * 
Almokalant 
271413 ** f QT 200411 234±11 2234:16 22248 278412** 263420 
QTc (C) 10 206 :^11 23649* 2264:13 26749 ** f 22847 27146** 259415 
QTc 03) 389422 438412* 4184:18 482416 431412* 48047** 463419* 
Quinidine 
QT 182±11 205±13 2144:15 225413 229413 321435** 270429 
QTc (C) 7 182±7 213±10# 2164:12 230410 232410 291423** 255419 
QTc(B) 33448* 406415** 3994:17 430412 ** 431412* 471421** 436414 
Amiodarone 
QT 204±12 207413 2204:15 221411 236413 23549 254416 
QTc (C) 8 209±10 2124:11 2184:11 21949 221411 22248 233413 
QTc(B) 391±14 394416 394±15 396413 380416 386414 394418 
QT, QT interval (ms); QTc (C), Carlsson's rate corrected QT interval (ms); QTc (B), Bazett's 
rate corrected QT interval (ms); Ventricular heart rate (see Table 6) was used for calculating 
rate corrected QT intervals. #P<0.05 vs. the value measured right before the beginning of the 
administration of the given dose; *P<0.05 vs. control group; fPO.OS vs. quinidine and 
amiodarone. See other details in Table 6. 
3.4. Examination of the antiarrhythmic effects of calcium channel blockers 
3.4.1. Effect of mibefradil and (^-verapamil on the ischemic and reperfusion arrhythmias 
Neither (±)-verapamil nor mibefradil at 10, 30 or 100 nM reduced VF incidence (Table 
8). VF was, however, abolished by higher concentrations of (±)-verapamil (300 and 600 nM). 
Mibefradil was less potent than (±)-verapamil, protective only at 600 nM. There were no 
significant drug effects on the incidence of ischemia-induced VT (100% in all groups), 
bigeminy, salvos or VPBs (data not shown). The onset times of the first episode of ischemia-
induced arrhythmias (all types) and VF were neither hastened nor delayed by mibefradil or (±)-
verapamil (data not shown). 
Only the highest concentration of (±)-verapamil reduced reperfusion-induced VF 
incidence significantly, and mibefradil was ineffective at all 5 concentrations (Table 8). 
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Neither drug at up to 100 nM caused AV block at any time during the experiment, and 
fewer than 20% of hearts in either drug group had AV block at 300 nM. However, 600 nM 
mibefradil and 600 nM (±)-verapamil caused AV block in most hearts during ischemia (Table 
8), and this was most commonly a mixture of Mobitz I and II. 
Mean occluded zone size was not affected by either drug and values ranged from 36 to 
41% (data not shown). 
Table 8. Arrhythmia incidences in isolated rat hearts perfused with calcium channel blockers 
during coronary artery occlusion and reperfusion 
Concentration 
Ischemia Reperfusion 
n AV block (%) VF(%) n VF (%) 
Control OnM 12 0 92 10 100 
Verapamil 10 nM 12 0 92 6 100 
30 nM 12 0 83 4 100 
100 nM 12 0 75 6 83 
300 nM 12 12 0* 11 73 
600 nM 12 58* 0* 12 42* 
Mibefradil 10 nM 12 0 83 8 88 30 nM 12 0 100 7 100 
100 nM 12 0 100 4 100 
300 nM 12 17 75 8 75 
600 nM 12 83* 17* 12 75 
n, number of hearts; AV block, atrioventricular conduction block; VF, ventricular fibrillation; 
Verapamil, (±)-verapamil; *P<0.05 vs. control. 
3.4.2. Effect of mibefradil and (±)-verapamil on the coronary flow and ECG intervals 
Mean baseline coronary flow (n=132) 1 min before perfusion with drugs was 13.4±0.3 
ml min'1 g'1 and there were no significant differences between groups. There was a small time-
dependent fall in flow in controls (Table 9). Both drugs increased coronary flow before the 
onset of ischemia, with effects significant at >100 nM (Table 9). Although the flow increases 
produced by 300 and 600 nM mibefradil tended to be greater than those elicited by equivalent 
concentrations of (±)-verapamil, the differences were not significant. Dining ischemia, flow fell 
step-wise to a similar extent in all groups and, during reperfusion, flow recovered to values at 
least as great as those before the onset of ischemia in all groups (data not shown). 
Pre-drug mean PR interval was 37±0.4 ms (n=132), and there were no significant 
differences between groups. PR interval was widened significantly only by 600 nM (±)-
verapamil 1 min before the start of ischemia (Table 9). During ischemia PR intervals could not 
be measured due to frequent occurrence of Mobitz I AV block. 
Pre-drug mean QT interval was 63±0.6 ms (n=132) and there were no significant 
differences between groups. At 1 min before the onset of ischemia, neither drug affected QT 
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interval (Table 9) but mibefradil at 600 nM widened QT interval from 15 min after the start of 
ischemia (101±6 vs. 79±2 ms in controls; P<0.05); the effect was still present after 5 min of 
reperfusion. (±)-Verapamil had no such effect (data not shown). 
Pre-drug heart rate was 336±3 min"1 (n=132) and there were no significant differences 
between groups. There was a small time-dependent M in heart rate in controls 1 min before 
the start of ischemia (Table 9), but neither drug affected heart rate at this time, and there was 
no trend to an effect of either drug during the remainder of the experiment (data not shown). 
Table 9. Change in coronary flow, PR interval, QT90 interval and heart rate induced by 
switching from control solution to intervention 5 min before the start of ischemia 
Change in 
Concentration n 
Coronary flow 
(ml min'1 g'1) 
PR interval 
(ms) 
QT90 interval 
(ms) 
Heart rate 
(min 1) 
Control OnM 12 -2.8±0.6 4±1 - l i l -37i7 
Verapamil 10 nM 12 -2.6±1.1 1±1 - l i l -3Ü8 30 nM 12 0.3±0.8 3±1 -3il -19i5 100 nM 12 5.7±0.6* 4±1 -4i l -7i7 
300 nM 12 4.8±0.9* 4±1 -5i2 -32il6 
600 nM 12 6.2il.0* 15±2* 2i2 -27i7 
Mibefradil 10 nM 12 -0.8±0.6 2±1 -2il -20i6 30 nM 12 3.4±0.8 0±1 -4i2 -10i6 100 nM 12 6.3±0.8* 3 i l - l i l -Ü7 300 nM 12 8.2il.O* 6 i l - l i l -10i6 600 nM 12 8.7Ü.2* 7 i l 2 i l -22il6 
n, number of hearts; QT90 interval, QT interval measured at 90% repolarization; Verapamil, 
(±)-verapamil; Values are changes measured at 1 min before the start of ischemia. *P<0.05 vs. 
control. 
3.5. Effect of elevated K + concentrations on the activity of calcium channel blockers 
3.5.1. Effect of mibefradil and (±)-verapamil on the developed ventricular pressure 
In a separate set of hearts, pre-drug baseline left ventricular developed pressure values 
were similar in each group, and were not dependent on perfusion K + concentration (Table 10). 
With the same inflation of the intraventricular balloon in each heart, the pressure development 
was equivalent to about 70% of maximum attainable for the preparation, as desired. Neither 
drug at up to 600 nM affected developed pressure when hearts were perfused with Krebs' 
containing 3 mM K + (Table 11). In contrast, when 6 mM K+ was used, 30, 100, 300 and 600 
nM (±)-verapamil reduced developed pressure significantly and concentration-dependently and 
by a maximum of approximately 70 mmHg (Table 11). However, mibefradil reduced pressure 
significantly only at 600 nM and by only approximately 30 mmHg. When 10 mM K + was used, 
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the effects of (±)-verapamil were further increased and mibefradil, though less potent than (±)-
verapamil, was active at >10011M (Table 11). 
Table 10. Pre-drug (baseline) left ventricular developed and diastolic pressures and coronary 
flow in rat hearts perfused with 3, 6 and 10 mM K + solutions 
Developed pressure Diastolic pressure Coronary flow 
n 3 mM K 6 mM K 10 mM K 3 mM K 6 mM K 10 mM K 3 mMK 6mMK lOmMK 
Control 10 99±12 106±5 92±13 3±10 -3±3 6±7 16.542.3 16.5±1.2 17.141.7 
Mibef 10 91±8 10043 117±6 1±3 242 -3±2 15.1±0.9 17.741.0 17.0±0.8 
Verap 10 82410 10244 11749 746 -2±1 -342 13.8±0.5 16.540.7 15.441.0 
n, number of hearts at each K + concentration; Control, vehicle groups (time and K+ matched 
control groups); Mibef mibefradil groups; Verap, (±)-verapamil groups. Pressure values are 
mmHg, coronary flow values are ml min' g~l. 
3.5.2. Effect of mibefradil and (±)-verapamil on the diastolic ventricular pressure 
In the same hearts, negative lusitropic effects on diastolic pressure (relaxation 
impairment, manifesting as an increase in end-diastolic pressure) mirrored changes in 
developed pressure, with high K + exacerbating the effects of both drugs, and (±)-verapamil 
being the more potent drug at each K + concentration. Baseline diastolic pressures were similar 
in each group, and were unrelated to perfusion K + concentration (Table 10). (±)-Verapamil at 
300 and 600 nM caused a small (maximum of approximately 5 mmHg) increase in diastolic 
pressure when hearts were perfused with Krebs' containing 3 mM K + (Table 11), whereas 
mibefradil was inactive. When 6 mM K + was used, 30, 100, 300 and 600 nM (±)-verapamil 
increased diastolic pressure significantly and concentration-dependently and by a maximum of 
approximately 18 mmHg (Table 11). However, mibefradil increased pressure significantly only 
at 600 nM and by less than 5 mmHg. When 10 mM K + was used, the effects of (±)-verapamil 
and mibefradil were further increased although mibefradil remained less effective than (±)-
verapamil at each concentration (Table 11). 
3.5.3. Effect of mibe fradil and (±)-verapamil on the coronary flow 
Baseline coronary flow in these hearts was not related to perfusion K + (Table 10). The 
baseline values were slightly higher than those in the arrhythmia study (see section 3.4.2.), 
presumably reflecting a slight vasodilatoiy response to the ventricular loading caused by 
balloon inflation. Flow was increased significantly to a similar extent by both drugs when K + 
was 3 mM (Table 11), just as it was in the earlier arrhythmia study (Table 9). The maximum 
increase in flow was ~6 ml min'1 g"1, and only 100 nM drug was required to achieve this. In 
contrast to effects on ventricular contractile function, the vascular effects of both drugs were 
diminished by raising K + to 6 mM (Table 11), and were absent at 10 mM K + (Table 11), and 
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there was no difference between (±)-verapamil and mibefradil in terms of these effects and 
their modification by K+. 
Table 11. Changes in left ventricular developed and diastolic pressures and in coronary flow 
following introduction of solutions of Ca 2 + channel blockers in rat hearts perfused with 3, 6 
and 10 mM K + solutions 
K+ Cone 
(mM) (nM) 
Change in developed pressure Change in diastolic pressure Change : in coronary flow 
Control Mibef Verap Control Mibef Verap Control Mibef Verap 
3 30 -17±7 6±4 -11±4 -2±1 -3i l Oil -2.9i0.8 3.4i0.9* 2.4i0.8* 
100 -19±10 8±7 -9±4 -1±2 -4i l Oil -2.8i0.8 6.3il.5* 6.1i0.5* 
300 -26±9 2±5 -20±5 0±2 -2i l 3 i l* -l.Oil.O 6.9il.7* 6.9i0.7* 
600 -28±9 0±4 -29±5 -1±2 - l i l 5 i l* -4.3Ü.6 6.2Ü.5* 6.0i0.8* 
6 30 -4±6 4±3 -44±8* 0±1 -2i l 5 i l* -1.Ü1.2 1.2il.l 0.8i0.7 
100 -4±6 1±5 -55i9* Oil - l i l 8 i l* -1.8Ü.1 3.0il.0* 2.4i0.8* 
300 -3 i l l -10±5 -72±5* l i l l i l 15il* -0.8Ü.8 2.2i0.7* 2.9t0.7* 
600 -3±10 -31±5* -72±3* Oil 4 i l * 18il* -1.9i2.1 2.2i0.8* 1.1 ±0.8 
10 30 1±4 -13±10 -70il2* -3i l - l i l 13i2* 0.5i0.9 2.Ü0.7 0.0i0.6 
100 -1±2 -23±4* -84il0* -3i2 2 i l 18il* 1.5Ü.2 3.Ü0.9 0.2i0.4 
300 -10±4 -63±2* -95Ü3* -2i3 l l i l * 22i l* 0.2il . l 2.4il.O* 0.5i0.7 
600 -16±7 -100±7* -113±18* -Ü3 16il* 23il* 2.1Ü.0 1.0i0.7 -0.Ü1.4 
Cone, concentration; Control, vehicle group (time and K + matched control group); Mibef, 
group of hearts perfused with sequentially increasing concentrations of mibefradil; Verap, 
group of hearts perfused with sequentially increasing concentrations of (±)-verapamil. Changes 
measured 4 min after the introduction of each drug solution. Pressure values are mmHg, 
coronary flow values are ml min"1 g"1; n=10 hearts/each drug at each K + concentration. 
*P<0.05 vs. control. 
3.6. Examination of the anti- and proarrhythmic effects of sodium channel blockers 
3.6.1. Effects of sodium channel blockers on the ischemic and reperfusion arrhythmias 
When perfusion solution with 3 mM K + was used, VF developed in almost all control 
hearts during ischemia (Table 12). In hearts in which VF was transient, subsequent reperfusion 
evoked a further episode of VF. Of the three Class I drugs, only flecainide reduced ischemia-
induced VF incidence significantly at the lower concentration (Table 12). In contrast all three 
drugs at the higher concentration reduced VF incidence during ischemia (Table 12). None of 
the drugs, even at higher concentration, had any effect on ischemia-induced VT, salvo, 
bigeminy or VPB incidences (data not shown). 
The incidence of reperfusion-induced VF was reduced significantly only by lidocaine 
and quinidine at the higher concentrations in hearts perfused with 3 mM K + (Table 12). None 
of the drugs, even at higher concentration, had any effect on reperfusion-induced VT, salvo, 
bigeminy or VPB incidences (data not shown). 
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In separate groups of hearts perfused with Krebs' modified to contain 5 raM K+, the 
control incidence of VF was low, as desired (Table 12). There were no statistically significant 
proarrhythmic effects of any of the drugs during ischemia or reperfusion, i.e. VF incidence was 
not increased (Table 12). Flecainide prevented ischemia-induced VT at the lower concentration 
(0 out of 6 vs. 6 out of 6 in control, P<0.05) although this effect was not significant for the 
higher concentration of the drug (3 out of 6 vs. 6 out of 6 in control). There were no 
significant drug effects on the incidence of ischemia-induced salvo, bigeminy or VPB in these 
hearts (data not shown). Similarly, none of the drugs affected the incidences of reperfusion-
induced ventricular arrhythmias (any kind) in this set of experiments. 
Mean occluded zone size was not affected by any of the drugs and values ranged from 
37-43 % of the total ventricular weight (data not shown). 
Table 12. The incidences of ischemic and reperfusion-induced ventricular fibrillation in 
isolated rat hearts perfused with sodium channel blockers 
3 mM K + in perfusate 5mMK + in perfusate 
ischemia reperfusion ischemia reperfusion 
n VF(%) n VF(%) n VF(%) n VF(%) 
Control (0 pM) 12 92 5 100 6 50 5 60 
Quinidine 0.79 pM 12 75 10 80 6 0 6 67 
Lidocaine 3.88 pM 12 58 9 89 6 0 6 83 
Flecainide 0.74 pM 12 17* 12 67 6 0 6 33 
Control (0 pM) 12 92 7 100 6 17 5 20 
Quinidine 7.90 pM 12 0* 12 42* 6 0 6 0 
Lidocaine 12.93 pM 12 17* 11 36* 6 0 6 33 
Flecainide 1.48 pM 12 17* 12 58 6 17 6 0 
VF, ventricular fibrillation; n, number of hearts; *P<0.05 vs. control. 
3.6.2. Proarrhythmic events evoked by sodium channel blockers 
A hastening of the mean onset time of the first ischemia-induced arrhythmia is 
indicative of a proarrhythmic drug effect. Arrhythmia onset was neither hastened nor delayed 
by any of the three drugs, whether hearts were perfused with Krebs' containing 3 or 5 mM K+ 
(data not shown). 
However, an unusual very early onset of ischemia-induced VF was observed in two 
hearts perfused with the higher concentration of flecainide. In one, a heart perfused with 
Krebs' containing 3 mM K+, VF occurred 294 s after the onset of ischemia (the equivalent 
value in K+-matched controls being 480 s). This was by far the earliest onset in the whole 
study. In the other, a heart perfused with Krebs' containing 5 mM K+, VF commenced 437 s 
after the onset of ischemia (the equivalent value in K+-matched controls being 1013 s). 
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Monomorphic VT lasting longer than 120 s and having a frequency higher than 1000 
min1 was a rare event, occurring in only 3 hearts (all perfused with Krebs' containing 3 mM 
K+), one during perfusion with the lower concentration of quinidine and one with the lower 
and one with the higher concentration of lidocaine. In addition, in one heart perfused with the 
higher concentration of flecainide and Krebs' containing 3 mM K+, monomorphic VT with a 
frequency of approximately 650 min"1 and with a duration longer than 120 s was observed. 
These unusual episodes of VT were not predictive of a susceptibility to any subsequent 
manifestation of VF. 
Flecainide and lidocaine concentration-dependently evoked sinus arrhythmias, 
manifesting as apparently random beat-to-beat variations of RR interval. When the K+ content 
of the Krebs' solution was 3 mM, sinus irregularity developed in 58, 33, 0 and 0% of hearts 
perfused with the higher concentration of flecainide, lidocaine, quinidine and vehicle, 
respectively (P<0.05 for flecainide compared to vehicle control). Irregular sinus rhythm 
developed in some hearts perfused with the lower concentration of flecainide and lidocaine, 
and in hearts perfused with Krebs' containing 5 mM K+, but under these circumstances the 
incidences were not significantly different from zero (appropriate K+-matched control group) 
(data not shown). 
3.6.3. Effects of sodium channel blockers on the coronary flow 
When hearts were perfused with Krebs' containing 3 or 5 mM K+, group mean baseline 
coronary flows 1 min before introducing drug-containing Krebs' ranged from 11.9±0.7 to 
14.9±0.5 ml min*1 g"1 and 13.8±0.7 to 16.5±0.6 ml min"1 g'1, respectively (no significant 
differences between drug groups and controls at either K+ concentration). Subsequent 
perfusion with drugs had no significant effect on coronary flow prior to occlusion. Coronary 
flow fell to a similar extent in all groups during coronary artery occlusion (data not shown). 
During reperfiision flow recovered to values at least as great as those before the onset of 
ischemia in all groups (data not shown). 
3.6.4. Effects of sodium channel blockers on the heart rate and ECG intervals 
In hearts perfused with Krebs' containing 3 mM K+, quinidine and (to a lesser extent) 
flecainide slowed heart rate during (but not before) ischemia with effects similar at the lower 
and higher concentrations (Table 13). When perfusate contained 5 mM K+, the bradycardic 
effect of the higher concentration of quinidine was exacerbated, and an equivalent effect of 
lidocaine was unmasked, whereas the effects of the lower concentration of quinidine (and 
effects of flecainide) were lost (Table 13). 
The effects of the drugs on PR interval were clearly concentration- and K+-dependent. 
When Krebs' contained 3 mM K+, all three drugs at the higher concentration widened PR 
interval significantly, with quinidine eliciting the greatest effect (Table 13); the lower 
concentrations had no effect. When Krebs' contained 5 mM K+, the effectiveness of the higher 
concentration of flecainide was increased, its actions becoming similar to those of quinidine, 
and the effects of the lower concentration of flecainide were potentiated to the extent that PR 
intervals exceeded those in hearts perfused with the lower concentration of quinidine (Table 
13). 
Table 13. Heart rate, PR interval and QT90 interval before and during coronary artery 
occlusion in isolated rat hearts 
K+ Cone 
(mM) (nM) n 
Heart rate (min"1) PR intervalO tns) QT90 interval (ms) 
Baseline -1 min IS min Baseline -1 min IS min Baseline -1 min IS min 
3 Control 0 12 332±8 309±7 283±10 37±1 38±1 40±2 65±2 64±2 74±1 
Quinidine 0.79 12 321±7 283±11 224±10* 39±1 39±1 40±2 65±2 70±2 88±4* 
Lidocaine 3.88 12 335±10 294±10 258±9 37±1 40±1 41±1 64±2 66±2 81±3 
Flecainide 0.74 12 333±10 302±9 251±6* 37±1 40±1 44±1 65±1 66±1 79±2 
Control 0 12 357±11 317±12 285±13 39±1 41±1 40±1 65±2 65±2 70±2 
Quinidine 7.90 12 379±9 284±12 243±12* 40±1 50±2* 55±2* 61±2 85±3* 109±5* 
Lidocaine 12.93 12 364±10 293±10 274±9 39±2 42±2 46±2* 66±1 66±3 76±2 
Flecainide 1.48 12 340±13 290±12 247±13 42±1 47±2* 48±2* 67±3 74±2 85±3* 
S Control 0 6 369±25 367±25 336±36 36±2 37±3 34±2 57±2 56±2 58±3 
Quinidine 0.79 6 401±15 354±18 319±25 37±1 39±1 42±2* 52±2 55±1 66±2 
Lidocaine 3.88 6 347±25 314±21 307±16 36±1 37±1 40±1 60±2 59±2 68±1 
Flecainide 0.74 6 407±28 355±35 320±20 35±3 41±3 45±2* 54±1 57±2 63±3 
Control 0 6 400±18 364±17 321±17 41±1 44±1 43±2 56±3 57±3 66±1 Quinidine 7.90 6 371±16 297±16* 248±9* 43±3 55±3* 57±1* 55±3 73±3* 81±3* 
Lidocaine 12.93 6 365±15 298±9* 271±16 41±2 47±2 47±2 55±1 62±3 72±2 
Flecainide 1.48 6 356±25 306±25 290±23 41±2 52±3 54±3* 56±3 61±3 72±2 
Cone, concentration; n, number of hearts; QT90 interval, QT interval measured at 90% 
repolarization; Baseline, values measured before switching Krebs' solution to test solution; -1 
min, values measured 1 min before coronary artery occlusion; 15 min, values measured in the 
15th min of ischemia; Control, vehicle groups (time and K+ matched control groups); *P<0.05 
vs. control. 
QT interval (measured at 90% repolarization) was mildly prolonged by the lower 
concentration of quinidine, when Krebs' solution contained 3 mM K+ (Table 13). However, the 
higher concentration of quinidine markedly and significantly widened QT interval (Table 13). 
This effect was substantially diminished, and its onset delayed, by perfusion with a higher 
concentration of K+ (5 mM) (Table 13). Additionally, this high K+ concentration itself 
shortened QT interval with all three drugs (Table 13). Flecainide mildly prolonged QT interval 
at higher concentration, when Krebs' solution contained 3 mM K+, but this effect was 
significant only at 15 min of ischemia (Table 13). 
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4. DISCUSSION 
4.1. The antiarrhythmic activity of potassium channel inhibitors 
In these studies the antiarrhythmic activity of intravenous ahnokalant and d-sotalol have 
been assessed in rabbits, and the results demonstrated that these drugs prevent reperfusion-
induced VF. Interestingly, K+ channel blockers e.g. d-sotalol, dofetilide, sematilide, E-4031and 
UK66,914 vary in their effectiveness against reperfiision arrhythmias. For example, in one 
study d-sotalol was found to be ineffective against ischemia and reperfiision induced 
arrhythmias in isolated guinea pig right ventricular free wall preparations [94]. In contrast, 
UK66,914 possessed marked antiarrhythmic effect on reperfiision arrhythmias in isolated 
rabbit hearts [95]. In another study d-sotalol, E-4031 and MS-551 (a non-selective K+ channel 
blocker) were effective against reperfiision arrhythmias and arrhythmias induced by 
programmed electrical stimulation, whereas dofetilide and sematilide prevented only 
arrhythmias induced by programmed electrical stimulation but did not suppress reperfiision 
arrhythmias in anesthetized dogs [96, 97]. 
4.1.1. The possible mechanism of antiarrhythmic action of almokalant and d-sotalol 
Reperfiision induced arrhythmias may be mediated both via reentry mechanism [98] and 
triggered activities [99, 100]. Selective prolongation of repolarization (class HI antiarrhythmic 
effect) is one possibility to prevent and terminate reentrant arrhythmias, but it has no effect on 
arrhythmias induced by triggered activities. Abrahamsson et.al. showed [101] that almokalant 
prolongs the action potential duration in a dose dependent manner both in isolated Purkinje 
and in ventricular muscle cells of the rabbit by recording transmembrane action potentials. 
Duker et al. [102] found that almokalant (1.0 mmol kg"1, i.v.) significantly prolonged the 
epicardial monophasic action potential duration and the atrial and ventricular effective 
refractory period but it had no effect on the atrial and ventricular conduction in anesthetized 
dogs. Similarly to almokalant, d-sotalol has been shown to prolong action potential duration 
and the corresponding refractory period (Class III antiarrhythmic effect) without affecting 
depolarization in guinea-pig papillary muscles, sheep and rabbit Purkinje fibers [103]. In the 
present study 88 pg kg'1 almokalant and d-sotalol (in the dose of 1 and 3 mg kg"1) significantly 
prolonged QTc interval, i.e. ventricular repolarization. Thus, the possible mechanism by which 
these drugs prevented reperfiision arrhythmias is the lengthening of the action potential 
duration and the refractory period of myocardial fibers (achieved by selective blockade of K+ 
channels) in the reentrant circuit to such an extent that the propagating reentrant impulse no 
longer finds excitable myocardium but blocks in refractory tissue. 
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4.2. The proarrhythmic effect of potassium channel inhibitors 
These studies have demonstrated that in anesthetized rabbits only d-sotalol and 
almokalant induced TdP, whereas quinidine and amiodarone did not. Moreover, our results 
showed that not only TdP but also other types of arrhythmias can be evoked by K+ channel 
inhibitors. Furthermore, we found no direct correlation between the occurrence of TdP and the 
infusion rate or the dose of antiarrhythmics when graded doses were applied with an interval 
between each dose. 
In the second set of proarrhythmia experiments (section 3.3.) we modified the protocol 
of Carlsson et al. [38, 55]. Instead of giving repolarization prolonging drugs in continuous 
infusions, we applied stepwise elevation of doses with an interval between each dose. This was 
for the following reasons: (i) According to Carlsson et al. [38] and our results with continuous 
almokalant infusions (section 3.2.) the infusion rate of drugs is an important predisposing 
factor for TdP. With our modified protocol, three different infiision rates were tested in one 
animal, which decreased the total number of animals required, (ii) Not only the dose 
dependence, but also the time dependence of the occurrence of arrhythmias can be compared 
between different treatment groups with this protocol as there is an interval between the 
administration of increasing doses of drugs. 
4.2.1. No torsade de pointes with quinidine 
In our experiments quinidine did not evoke TdP, though this drug was by far the most 
frequently reported drug associated with this arrhythmia [25]. In patients with TdP due to 
quinidine, the plasma level of the drug is usually within or below the therapeutic range [30]. 
Quinidine's clinical proarrhythmic profile (especially the dose-dependence) is not mimicked in 
any of the presently available animal proarrhythmia models. In anesthetized dogs Inoue and 
Sugimoto [104] used toxic dose of quinidine (30 mg kg'1 over 5 min, i.v.) to evoke TdP. 
Despite the observation that this dose prolonged QT in their study, TdP never occurred 
spontaneously and required additional programmed electrical stimulation to evoke it. Likewise, 
in conscious hypokalemic dogs with chronic complete AV block TdP did not occur 
spontaneously during or after a continuous infiision of quinidine (~20 mg kg'1 over 3 hour), 
though QT interval was widened significantly by this dose [105]; and an additional propranolol 
infusion was necessary to allow the generation of TdP in that study. In methoxamine-primed 
anesthetized rabbits continuous quinidine infusion (1.25 mg kg'1 min'1 for 60 min) did not 
evoke TdP despite of increasing QT, QTc and QT dispersion significantly [106], but on the 
other hand, the drug evoked conduction blocks frequently [106]. Thus, the lack of quinidine 
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induced TdP in the present study is in a good accordance with the results of the previous in 
vivo animal studies. 
In our investigations, in contrast to d-sotalol and almokalant, only the highest dose of 
quinidine prolonged QT intervals whereas QTc was already prolonged by the lower doses. 
Moreover, the 2nd dose of quinidine was less potent in prolonging either QT or QTc intervals 
than the middle dose of almokalant and d-sotalol. This smaller QT and QTc prolonging 
potency might be a reason for the little proarrhythmic activity of the lower doses of quinidine 
in the present study. However, TdP was also absent even when marked QT and QTc 
prolongation were achieved by the highest dose of quinidine. This observation accords well 
with that of Lu et al. [106] and suggests that QT or QTc prolongation and increased QT 
dispersion [106] are not the only contributing factors to TdP generation in Carlsson's rabbit 
model. 
The high heart rate of the rabbit compared to that of man could also contribute to the 
blunted proarrhythmic activity of quinidine compared with its effects in man. At high 
frequencies quinidine's Na+ channel inhibiting property is increased (use-dependent block) 
[107], which may prevent TdP at these high heart rates of the rabbit [108]. In addition, after 
the administration of the 1st dose of quinidine, its antimuscarinic action on atrial muscarinic 
receptors [109] and/or its blood pressure lowering effect might prevent phenylephrine-induced 
reflex bradycardia, which could predispose to TdP. However, this lack of reflex bradycardia 
became irrelevant especially after the administration of the 3rd dose of quinidine, as this dose 
decreased the ventricular rate markedly due to frequent occurrence of 2:1 and total AV blocks. 
However, this relatively low ventricular rate, which coincided with marked QT and QTc 
prolongation, was still insufficient to allow generation of TdP. Likewise, quinidine and 
terfenadine reduced heart rate and prolonged QT and QTc markedly without evoking TdP in 
ai-adrenoceptor stimulated rabbits [106]. These suggest that low ventricular (or heart) rate 
and prolonged QT and QTc intervals are not the only contributing factors to TdP generation in 
the rabbit model of the acquired long QT syndrome. 
In the present investigation quinidine dose dependency lowered blood pressure and the 
pressure drops were significantly greater than those with any other drug. In methoxamine 
sensitized anesthetized rabbits [106] terfenadine and quinidine reduced blood pressure to a 
very low level and did not evoke TdP despite of increasing QT, QTc and QT dispersion and 
reducing heart rate. In contrast, clofilium and dofetilide had much milder effect on the blood 
pressure and evoked TdP while having similar QT, QTc, QT dispersion and heart rate effect 
than quinidine and terfenadine in the same study [106]. These suggest that marked blood 
pressure reduction may prevent TdP generation in the anesthetized rabbit model. 
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Quimdine inhibits ai-adrenoceptors competitively at therapeutic blood levels [110], 
thereby preventing the complex sensitizing effect of ai-adrenoceptor stimulation in this animal 
model. A similar effect was seen in a recent study in which cisapride, a potent inhibitor of IKT 
was found to have very low proarrhythmic potential in the rabbit model of acquired long QT 
syndrome [111]. This was attributed to the drug's high ai-adrenoceptor blocking potency. 
4.2.2. No torsade de pointes with amiodarone 
Intravenous amiodarone did not induce ventricular tachyarrhythmias and did not 
prolong significant^ QT and QTc in our experiments. Although proarrhythmic events are very 
rare in patients treated with intravenous amiodarone [34], the drug can evoke TdP in man [34, 
112, 113]. In rabbits, the time of maximal uptake of i.v. bolus amiodarone by the myocardium 
has been estimated as between 5 and 15 min [114]. Therefore, low accumulation of 
amiodarone in our experiments cannot be responsible for the low proarrhythmic activity. 
Intravenously administered amiodarone inhibits the delayed rectifier outward K+ current ( IK) , 
the inward Na+ current (INa) and the inward L-type Ca2+ current (ICB-L) [115, 116]. The 
simultaneous inhibition of IK and INa or IK and ICa-L, achieved by combination of selective 
inhibitors, has been shown to have low proarrhythmic activity in Carlsson's rabbit model [61, 
62, 108, 117] probably due to the EAD suppressing or repolarization prolongation limiting 
effect ofICa.LandINa inhibition, respectively. Intravenous amiodarone inhibits a-adrenoceptors 
in a non-competitive manner [118], which could also contribute to the low proarrhythmic 
activity of the drug in this model. 
4.2.3. Complex proarrhythmic response to iC channel blockers: not only torsade de pointes 
Class III agents typically produce TdP. However, in a clinical study ibutilide and sotalol 
induced not only TdP but also monomorphic VT in patients with atrial fibrillation or flutter 
[119]. Darpo et al. [41] reported a case in which an almokalant treated patient with WPW 
syndrome developed TdP after a pacing induced pause, and this tachycardia degenerated into 
VF that required immediate defibrillation. In our experiments almokalant and d-sotalol (during 
ai-adrenoceptor stimulation) produced monomorphic and polymorphic VT and sustained VF 
as well as TdP. Carlsson et al. [38, 55] reported only on premature ventricular complexes and 
TdP induced by class m agents in rabbits. Maybe this discrepancy is attributable to the fact 
that the latter authors terminated their experiments at the time of the first appearance of TdP. 
However, in our proarrhythmia study with continuous almokalant infusions two animals 
developed VT prior to the first TdP and one developed VT without the occurrence of TdP. 
Likewise, Buchanan et al. [48] observed frequently the development of wide complex 
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tachycardia, which was not pause dependent like TdP following administration of class III 
agents. 
4.2.4. Torsade de pointes with increasing doses of d-sotalol and almokalant 
In the second proarrhythmia study only d-sotalol and almokalant induced TdP. 
Moreover, these drugs induced large number of VT and non-complex arrhythmias, e.g. VPB, 
bigeminy and salvo. In fact, TdP was always preceded by frequent occurrence of non-complex 
arrhythmias and sometimes VT. On the other hand, similarly to quinidine, d-sotalol and 
almokalant also induced conduction blocks in a dose related manner. This accords well with 
the results of Lu et al. [106] who showed that the selective IKF blocker dofetilide and the non-
selective IKr blocker clofilium, quinidine and terfenadine evoke conduction blocks frequently 
in ai-adrenergically stimulated rabbits. The primary targets of kr blockers are the cells of the 
conductive system and the M cells [28]. Extreme repolarization and refractory period 
prolongation of these cells may lead to blocks, especially at the relatively short cycle length of 
the rabbit. The initiating mechanism of TdP is probably related to VPB whereas the 
maintenance mechanism related to reentry [26, 28]. Thus, frequent non-complex arrhythmias 
and conduction blocks may play a role in the generation of TdP and other reentrant 
arrhythmias e.g. VT and VF in the rabbit model of acquired long QT syndrome. 
In our proarrhythmia study TdPs induced by either d-sotalol or almokalant were always 
preceded by markedly prolonged QT and QTc intervals, elevated blood pressure and relatively 
slow ventricular rate. In contrast, neither these factors coincided nor TdP developed in 
amiodarone and quinidine treated animals. These suggest that the coincidence of markedly 
prolonged QT and QTc intervals, elevated blood pressure and slow ventricular rate may be a 
prerequisite of TdP generation in the presently utilized animal model. 
In the present investigation almokalant and d-sotalol showed different proarrhythmic 
profile in terms of ventricular tachyarrhythmia onset. These arrhythmias occurred earlier during 
or after the administration of the middle dose of almokalant than those after the administration 
of the middle dose of d-sotalol. This earlier onset of ventricular tachyarrhythmias coincided 
with elevated sinus rate in the almokalant group, whereas the effects of d-sotalol and 
almokalant were not different on the QT and QTc intervals, ventricular rate and blood 
pressure. This suggests that not only QT and QTc prolongation, relatively low ventricular rate 
and elevated blood pressure play a role in arrhythmia genesis in the rabbit model of TdP. 
Similarly to our findings, the proarrhythmic effects of these two relatively selective K+ channel 
blockers were different in a dog TdP model [39]. Although both drugs widened QT in that 
study [39] too, only almokalant evoked TdP spontaneously, while programmed electrical 
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stimulation was necessary to initiate this arrhythmia in d-sotalol treated animals. In that study 
almokalant increased the interventricular dispersion of repolarization and the number of EADs 
to a greater degree than d-sotalol. 
Almokalant is a selective IRT inhibitor [35], whereas d-sotalol inhibits IRT and other K+ 
currents, i.e. It0 and IKi [42]. This difference in K+ channel selectivity, or d-sotalol's residual |3-
adrenoceptor blocking property [120] or possible differences between the time-course of the 
development of repolarization dispersion between the drugs might play a role in this different 
proarrhythmic profile of the two drugs. 
4.2.5. Infusion rate of antiarrhythmics and occurrence of torsade de pointes 
In our first proarrhythmia experiments continuous almokalant infusion at a higher rate 
induced more TdP than the infusion of almokalant at a lower rate. This accords well with the 
findings of an earlier study with continuous almokalant infusions performed by Carlsson et al. 
[38]. They reported that the occurrence of TdP is dependent on infusion rate. Their suggestion 
was that this was fundamental to the occurrence of TdP [38]. Interestingly, in our second 
proarrhythmia study when graded doses of K+ channel inhibitors were applied there was no 
direct correlation between the occurrence of TdP and the infusion rate or the dose of d-sotalol 
and almokalant, since the percentage incidences of this arrhythmia were greatest after the 
administration of the middle doses of the drugs. Our data demonstrate, that dependence on 
infusion rate may be particular to the continuous infusion and not to short-term infusions. 
4.3. The antiarrhythmic effects of calcium channel inhibitors 
We compared mibefradil with (±)-verapamil for effects on arrhythmias induced by 
ischemia and by reperfusion. By considering effects on the AV node and the coronary 
vasculature, and the ability of elevated extracellular K+ to influence the actions of the drugs on 
ventricular contractile function, we attempted to link the suppression of VF with blockade of L 
and T-channels. 
4.3.1. Actions of (±)~verapamil 
(±)-Verapamil is not selective for the myocardial L-channel. However, there is 
compelling evidence that actions such as a-receptor blockade, Na+ channel block, recruitment 
of collateral flow and bradycardia do not contribute to its effects on VF when examined in 
conscious rats [64], Importantly, the (+)- to (-)-verapamil potency ratio for effects on 
ischemia-induced VF in vivo correlates with the negative inotropic potency ratio in hearts 
perfused with high, but not low K+ containing solution. This finding, together with other 
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observations [63], indicates that L-channel blockade within the ischemic region (in which 
extracellular K+ levels are elevated) folly accounts for (±)-verapamil's effects on VF during 
ischemia in conscious rats. 
In the present study, the lack of effect of low concentrations of (±)-verapamil on VF 
was unsurprising, despite evident coronary vasodilatation. The rat heart is collateral-deficient 
[S3], so vasodilatation does not confer protection against ischemia-induced VF in this species 
[64, 72]. The lack of effect of (±)-verapamil on QT interval rules out the possibility that 
unforeseen Class lH and bradycardic actions contributed to its effects on VF. 
The effects of (±)-verapamil on systolic and diastolic pressure were similar to those 
observed previously with its (+) and (-) enantiomers [64], Developed pressure was reduced by 
more than 90% only in hearts perfused with 10 mM K+, and only by 300 or 600 nM (±)-
verapamil. It is noteworthy that only these higher concentrations of (±)-verapamil reduced 
ischemia-induced VF in the parallel study. The importance of this is that during early 
myocardial ischemia, local extracellular K+ concentration in the involved region rises to 10 mM 
and beyond [121]. 
The data therefore illustrates, for the first time, that (±)-verapamil's protective effects 
on ischemia-induced VF in conscious rats [63, 89] are mirrored by similar actions in vitro, and 
appear to be mediated by the same mechanism, namely L-channel blockade in the involved 
region. 
4.3.2. Actions of mibefradil 
T-channels are not considered to play any significant role in human ventricular 
myocardium [122]. In the rat heart, unpublished studies have foiled to detect measurable T-
channel activity (Shattock, personal communication). Thus, any effect of mibefiadil on VF 
would be expected to be more likely to result from L-channel blockade. If the response profile 
of mibefradil differed qualitatively from that of (±)-verapamil, we would have required to 
question this notion. However, we found that mibefradil exhibited a pattern of activity on most 
variables that was qualitatively identical to that of (±)-verapamil. 
Mibefradil suppressed ischemia-induced VF, but it was less potent than (±)-verapamil. 
Both drugs produced similar significant effects on coronary flow before ischemia, and both 
caused a similar degree of AV block. Mibefradil also resembled (±)-verapamil in terms of its 
lack of effect on heart rate. Mibefradil's profile of activity is therefore similar to that of (±)-
verapamil. However, this is insufficient in itself to prove that mibefradil suppressed VF solely 
by blocking L-channels. 
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4.3.3. Mechanism of action of mibefradil on ischemia-induced VF 
The role of L-channel blockade is much strengthened by considering the effects of K+ 
on the inotropic and lusitropic effects of mibefradil compared with (±)-verapamil. Mibefradil 
had little or no effect on contractility when K+ was normal. Likewise, only concentrations in 
excess of those used in the present study affected cardiac contractility in human [122] and 
guinea pig [123] studies. The negative inotropic and lusitropic effects of mibefradil were 
exacerbated by high K+, but the magnitudes of the responses were less than those produced by 
(±)-verapamil. Importantly, each drug reduced developed pressure by more than 90 mmHg 
only in hearts perfused with 10 mM K+, and the concentrations achieving this were the only 
ones that significantly reduced the incidence of ischemia-induced VF in the parallel study. 
Mibefradil does not affect IKI, a current important in arrhythmogenesis in rat heart [91] 
at up to 30,000 nM [124]. Nor does it reduce evoked norepinephrine release from sympathetic 
nerves at a concentration (IC50 1000 nM) relevant to present findings [125]. Likewise, the IC50 
for its effects on free-radical mediated cellular injury is 2,000 nM [126]. This limits the scope 
for L-channel-independent effects of mibefradil on VF in the present study. 
Thus, the overall response profile suggests that the antiarrhythmic effect of mibefradil 
was mediated by the same molecular mechanism as that of (±)-verapamil, and that this 
mechanism was the same as that responsible for effects on contractile function. The present 
findings imply that mibefradil reduced ischemia-induced VF by K+-dependent L-channel 
blockade within the involved region, without any contribution from additional actions 
(including T-channel blockade), differing from (±)-verapamil only in terms of potency. 
4.3.4. Properties limiting efficacy of (±)-verapamil and mibefradil on ischemia-induced VF 
Both (±)-verapamil and mibefradil were compromised by their ability to elicit AV block 
and increase coronary flow. The latter effect of (±)-verapamil is matched, in vivo, by a 
tendency to dilate other blood vessels leading to a sharp fall in blood pressure at doses 
associated with VF suppression [127]. The ratio of vascular to myocardial selectivity has been 
examined previously for mibefradil and (±)-verapamil, and mibefradil was found to be 
approximately 200 times more vascular selective than (±)-verapamil [128]. Likewise, in the 
present study both drugs affected coronary flow at concentrations much lower than those 
affecting VF. This marked vascular effect along with the AV block eliciting effects of these 
Ca2+ channel inhibitors preclude their use as antifibrillatory agents. 
4.3.5. Reperfusion-induced VF and other observations 
The effect of the drugs on reperfusion-induced VF was a minor focus of the study. It 
was interesting to note that both drugs were much less effective in suppressing reperfusion-
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induced VF than ischemia-induced VF, and significant activity was observed only with the 
highest concentration of (±)-verapamil. Reperfusion causes rapid wash-out of K+ from the 
extracellular space [121], and this resolves the ischemia-induced diastolic depolarization. In 
view of the voltage dependence of the actions of the drugs on L-channels (see above), 
blockade by each drug can be expected to be diminished by reperfusiom This would explain the 
limited ability of each drug to affect reperfusion-induced VF compared with ischemia-induced 
VF. 
The present data may also explain an earlier observation that electrically-induced 
arrhythmias in non-ischemic hearts are resistant to suppression by mibefradil and (±)-
verapamil, whereas electrically-induced arrhythmias in ischemic hearts are suppressed by both 
drugs [129]. Furthermore, they are in agreement with an observation that arrhythmias during 
ischemia in dogs are suppressed by lower doses of mibefradil than those required to suppress 
electrically-induced arrhythmias [130]. Each of these observations further point to an ischemia-
selective L-channel dependent mechanism of action. 
4.4. The anti- and proarrhythmic effects of sodium channel blockers 
Of the three representative Class I agents, only flecaimde (Ic) prevented phase-1 
ischemia-induced VF at the human 'therapeutic' free plasma concentration in isolated rat 
hearts. Quinidine (la) and lidocaine (lb) prevented phase-1 VF only at the human 'therapeutic' 
total blood concentration, which is much greater than the free plasma concentration, and 
therefore inappropriately high in terms of clinical relevance. None of the three Class I 
antiarrhythmics prevented reperfusion-induced VF at the human 'therapeutic' free plasma 
concentration. Since each of these types of VF (phase-1 and reperfusion-induced) potentially 
contribute to sudden cardiac death, the inability of these agents to achieve complete VF 
suppression at concentrations equivalent to the 'therapeutic' free plasma concentration may 
explain their poor clinical efficacy. 
4.4.1. The antifibrillatorv effect of quinidine 
The effect of quinidine on phase-1 ischemic VF has never been examined in isolated 
hearts before. In the present study quinidine prevented phase-1 VF only at an inappropriate 
high concentration (7.90 pM). This accords with published in vivo animal studies in which 
phase-1 VF was suppressed only by a very high dose (10 mg kg*1 i.v.) that adversely affected 
hemodynamic status in conscious and anesthetized rats [82, 131-133], anesthetized rabbits 
[54], pigs and dogs [82]. 
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Quinidine reduced the incidence of reperfusion-induced VF only at a very high 
concentration (7.90 pM). This accords with other studies with isolated Langendorff-perfused 
rat hearts in which only inappropriately high concentrations of quinidine (4-30 pM) were found 
to prevent reperfusion VF after regional [134, 135] or global ischemia [136]. However, 
quinidine was ineffective at 'therapeutic' concentration in the present study and this lack of 
effect accords with the lack of clinical effectiveness against sudden cardiac death (and may 
contribute to the lack of clinical effectiveness). In studies in vivo, quinidine prevented 
reperfusion VF at a high dose of 10 mg kg"1 i.v. in anesthetized rats and dogs [82], while even 
this dose was ineffective against reperfusion-induced VF in anesthetized pigs [82]. Overall our 
results with quinidine accord with published in vitro and in vivo animal studies. 
4.4.2. The antifibrillatory effect oflidocaine 
Lidocaine did not influence the incidence of phase-1 ischemic VF at the human 
'therapeutic' free plasma concentration (3.88 pM), whereas the drug was effective at the 
human 'therapeutic' total blood concentration (12.93 pM). This finding is in agreement with 
some, but not all published studies. In isolated guinea pig hearts only an inappropriately high 
concentration (10 pM) abolished VF during low flow global ischemia [137]. In contrast, a free 
concentration equivalent to the human 'therapeutic' free plasma concentration prevented 
phase-1 VF in blood perfused isolated pig hearts [138]. However the 'drug effect' may have 
been an artefact since the study design incorporated repetitive ligation and reperfusion, which 
could have preconditioned these pig hearts. In studies in vivo, only high and toxic doses of 
lidocaine (> 7-10 mg kg"1) prevented phase-1 ischemic VF in anesthetized [132, 133, 139, 140] 
and conscious [131] rats. Furthermore, even high doses of the drug did not prevent phase-1 
VF in anesthetized rabbits [141] and pigs [82, 142]. Similarly, neither low nor high doses of 
lidocaine abolished phase-1 ischemic VF in anesthetized dogs [82,143-146]. 
Like quinidine, lidocaine reduced the incidence of reperfusion VF only at the higher 
concentration (12.93 pM, 3 mM K+ in Krebs') in our experiments. Similarly to our results, 10 
pM lidocaine significantly decreased the incidence of reperfusion VF in isolated Langendorff-
perfused [140] and working rat hearts [147] after regional ischemia. In other studies, only 
extremely high concentrations of lidocaine (30-35 pM) prevented reperfusion-induced VF in 
isolated rat hearts after regional ischemia [135, 148]. The minimum protective concentrations 
of lidocaine against reperfusion VF were also very high (15-20 pM) after regional ischemia in 
isolated working rabbit hearts [149] and after global ischemia in isolated Langendorff-perfused 
guinea pig hearts [150]. Interestingly, even 30 pM lidocaine did not decrease the incidence of 
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reperfusion-induced VF in one study after global ischemia in isolated Langendorff-perfused rat 
hearts [136]. In vivo, reperfusion VF was abolished by a relatively high dose (5 mg kg"1, i.v.) 
of lidocaine after coronary artery occlusion in anesthetized rats [151]. On the contrary, this 
arrhythmia was not prevented even by 10 mg kg"1 i.v. lidocaine in anesthetized pigs [82]. 
Likewise, the drug had no protective effect against reperfusion-induced VF in anesthetized 
dogs [144-146,152]. 
Thus lidocaine, like quinidine has little or no effect on ischemia-induced or reperfusion-
induced VF when appropriate and tolerable concentrations or doses are examined in a wide 
range of models, including the isolated perfused rat heart. 
4.4.3. The antifibrillatorv effect of flecainide 
The effect of flecainide on ischemia induced phase-1 VF has never been examined in 
isolated heart preparations. In our study, this drug was the only representative Class I 
antiarrhythmic that prevented ischemic VF at the human 'therapeutic' free plasma 
concentration (0.74 pM). Similarly to our results flecainide (2 mg kg'1, i.v.) reduced the 
incidence of ischemic VF in vivo, in anesthetized rats [132, 133, 153]. In contrast, the same 
dose of the drug did not reduce the incidence of phase-1 ischemic VF in anesthetized pigs 
[154, 155] or anesthetized dogs [156]. 
Unlike the other two representative Class I agents, flecainide even at high 
concentration (1.48 pM) had no significant effect on reperfusion-induced VF in our 
experiments. On the contrary, flecainide at an inappropriately high concentration (1 pM) 
decreased the incidence of reperfusion-induced VF after low flow global ischemia in an other 
study in Langendorff-perfused rat hearts [157]. Similarly, the drug abolished reperfusion-
induced VF in vivo, at 2 mg kg"1 i.v., in anesthetized dogs [156]. 
Although the results of the present study with flecainide differ from those in some 
previous animal experiments, neither this study nor the previous ones show an unequivocal 
antifibrillatory effect of flecainide, or comprehensive suppression of both phase-1 ischemia-
induced and reperfusion-induced VF at clinically relevant concentrations. 
4.4.4. The proarrhvthmic effects of sodium channel inhibitors 
In the present study none of the Class I antiarrhythmics increased the incidence of 
phase-1 ischemic VF (even as a trend) when 5 mM K+ was used in the perfusate in order to 
keep the control VF incidence at a low level. However, sporadic proarrhythmic events (e.g. a 
very early onset of ischemia-induced VF in a minority of hearts, and induction of sustained 
monomorphic VT) occurred. Despite the lack of attainment of statistical significance, an 
39 
appearance of possible proarrhythmic events is regarded presently as a cause for concern in 
drug development [60]. Interestingly, there are no published isolated heart studies to date 
showing statistically significant proarrhythmic effects of Class I agents on arrhythmia onset 
times or incidences. However, lidocaine reduced the mean time to onset of phase-1 ischemic 
VF in a study in vivo in anesthetized rabbits [141]. Likewise, lidocaine and flecainide reduced 
the mean time to onset of phase-1 ischemic VF in anesthetized pigs [82, 155]. Furthermore, 
lidocaine increased the incidence of phase-1 ischemia-induced VF in anesthetized rabbits [141], 
pigs [158] and in anesthetized [159] and conscious dogs [160]. Lidocaine also increased the 
incidence of reperfusion VF in anesthetized dogs [82]. 
These studies suggest that proarrhythmic effects of Class I drugs during ischemia and 
reperfusion are easier to evoke in in vivo models compared with isolated perfused hearts. 
Perhaps the presence of an autonomic nervous system, hormones, and other events such as 
heart rate variability, are necessary for proarrhythmic drug effects to reach a threshold for 
arrhythmia manifestation. It is also possible that there are species differences in sensitivity to 
proarrhythmia, i.e., larger animals (e.g. rabbit, pig and dog) may be more sensitive than rats 
and guinea pigs. 
It is well known that proarrhythmic drug effects in man are more common where there 
is chronic heart diseases [65, 77] such as established infarction. Indeed, the unexpected effects 
of flecainide in the Cardiac Arrhythmia Suppression Trial have been attributed to an interaction 
between the drug, a new episode of ischemia and an old infarct [161], a set of conditions that 
are not mimicked in isolated heart preparations subjected to acute ischemia and/or reperfusion. 
If this is correct then the isolated heart models of acute ischemia and reperfusion (such as the 
present) that show minimal proarrhythmia in response to Class I drugs may be better reflective 
of clinical susceptibility to proarrhythmia in the absence of chronic heart disease than the in 
vivo acute ischemia models that show greater susceptibility to Class I proarrhythmia (and 
which would therefore be inappropriately sensitive to proarrhythmic drug effects). 
4.4.5. Ancillary pharmacological actions of sodium channel inhibitors 
Drug effects on heart rate, QT and PR interval, and coronary flow can give an 
indication of mechanisms underlying drug actions on arrhythmias. In the present study 
ischemia-induced and reperfusion-induced VF were not affected by clinically relevant drug 
concentrations (with the exception of flecainide's actions on ischemia-induced VF). Thus, drug 
effects on ancillary variables are interesting only in relation to their presence being indicative of 
the presence of "pharmacologically active" drug concentrations. 
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There were no substantial or consistent drug effects on heart rate that related to VF 
suppression (or the lack of suppression) in any way. PR interval was widened in a 
concentration-dependent manner that was exacerbated by high K+, and is thus consistent with 
Na+ channel block in the AV node [86]. This is encouraging evidence that the drug 
concentrations studied were pharmacologically active at their primary molecular target, the 
Na+ channel. 
Of the 3 drugs, only quinidine had substantial effects on QT interval. This, together 
with the observation that elevating the K+ content of the perfusion solution reversed the QT 
widening effect of quinidine, is consistent with the known relative selectivity of the three drugs 
for Na+ vs. K+ channels, quinidine being the least selective [86]. In the rat heart, which does 
not express functional IK [162], quinidine's QT widening effects are exclusively attributable to 
blockade of It0 [163]. In short, the QT and PR prolonging effect of quinidine shows that the 
concentrations of the drug studied were pharmacologically active at both Na+ and K+ channels. 
5. CONCLUSIONS 
Our K+ channel blocker studies have provided evidence that almokalant and d-sotalol 
are effective against reperfiision VF, though they have marked proarrhythmic effects during 
ai-adrenoceptor stimulation in anesthetized rabbits. Furthermore, these studies demonstrated 
experimentally that almokalant and d-sotalol are able to produce not only TdP as a malignant 
proarrhythmia, but also VT (different from TdP) and VF. This high propensity of these drugs 
to evoke severe proarrhythmia compromises their antiarrhythmic efficacy and precludes then-
use as antifibrillatory agents. Our results also suggest that the incidence of TdP may not 
depend on the infusion rate or the dose of antiarrhythmics when graded doses are applied with 
an interval between each dose. Furthermore, TdP generation may be a multifactorial process in 
the rabbit model of TdP and the contributing factors may be slightly different from those in 
man. Thus, drugs which have different pharmacodynamic actions at high heart rates (seen in 
the rabbit) compared with effects at lower heart rates (seen in man), drugs which decrease 
blood pressure markedly or drugs, which possess ai-adrenoceptor inhibitory effects, could 
elicit a false negative outcome (i.e., low proarrhythmic activity) in the rabbit model of TdP. 
As a conclusion of the Ca2+ channel inhibitor study, mibefradil is less potent than (±)-
verapamil as an antiarrhythmic agent in ischemic rat ventricle. The effects of both drugs can be 
explained on the basis of L-channel blockade within the ischemic region. Neither drug is 
sufficiently ischemia-selective to achieve protection against VF at concentrations devoid of 
potentially hazardous vascular and AV nodal effects. This not only serves to explain the lack of 
efficacy of (±)-verapamil in preventing sudden cardiac death in man [65], but also excludes the 
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possibility of mibefradil (or a pharmacologically similar analogue) possessing better efficacy. It 
also appears from the Ca2+ channel inhibitor study that the T-channel is unlikely to represent a 
useful molecular target for VF suppression. 
Regarding the Na+ channel inhibitor study, the ischemia-selective VF suppression by 
flecainide, and the ineffectiveness of clinically relevant concentrations of quinidine and 
lidocaine during both ischemia and reperfusion, despite evidence ofNa+ channel blockade and 
(in the case of quinidine) K+ channel blockade, confirms that the spectrum of antiarrhythmic 
activity of Class I agents in the isolated rat heart is narrow and weak at the equivalent of 
clinically safe 'therapeutic' concentrations. Moreover, there was a tendency for proarrhythmia 
with flecainide (early VF onset and sustained monomorphic VT), despite an overall reduction 
in ischemic VF incidence. These findings are consistent with, and may explain, the limited 
effectiveness of these Na+ channel inhibitors against sudden cardiac death in man. Since none 
of the Class I drugs were proarrhythmic in ischaemic hearts in which arrhythmia susceptibility 
had been lowered by high K+, it would appear that clinical proarrhythmia seen with these drugs 
may not be related to exacerbation of phase-1 ischaemia-induced VF. 
These results gave experimental evidence of proarrhythmic activity or limited 
effectiveness of representative agents of three major classes of antiarrhythmics and the 
methods applied provide useful experimental tool for examining both the effectiveness and the 
harmful effects of newly developed antiarrhythmic agents. 
6. NEW FINDINGS 
1. Almokalant and d-sotalol prevent reperfusion VF in anesthetized open chest rabbits. It 
appears that the incidence of TdP may not depend on the infusion rate or the dose of 
antiarrhythmics when graded doses are applied with an interval between each dose. 
Furthermore, TdP generation may be a multifactorial process in the rabbit model of TdP 
and the contributing factors may be slightly different from those in man. 
2. Mibefradil is not sufficiently ischemia-selective to achieve protection against VF at 
concentrations devoid of potentially hazardous vascular and AV nodal effects in isolated 
Langendorff-perfiised rat hearts. The antifibrillatory effect of mibefradil can be explained 
on the basis of L-channel blockade within the ischemic region and T Ca2+ channel is 
unlikely to represent a useful molecular target for VF suppression. 
3. The spectrum of antiarrhythmic activity of representative Class I agents in the isolated rat 
heart is narrow and weak at the equivalent of clinically safe 'therapeutic' concentrations 
and the clinical proarrhythmia seen with these drugs may not be related to exacerbation of 
phase-1 ischemia-induced VF. 
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